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MICAL	   (Molecule	   Interacting	   with	   CasL)	   is	   a	   1048	   amino	   acid	   protein	  
consisting	  of	  a	  flavin-­‐containing	  monooxygenase	  domain	  (FD)	  with	  redox	  activity,	  a	  
Calponin	  homology	  (CH)	  domain,	  a	  LIM	  (Lin-­‐11,	  Isl-­‐1,	  Mec-­‐3)	  domain,	  a	  proline-­‐rich	  
region,	   and	   a	   C-­‐term	   region	   containing	   coiled-­‐coil	   ERM	   α-­‐like	   domain.	   In	   axon	  
guidance,	   MICAL	   is	   a	   key	   molecule	   that	   links	   the	   extracellular	   signal	   from	  
semaphorins	   –a	   class	   of	   repulsive	   guidance	   cues–	   to	   the	   reorganization	   of	   the	  
cytoskeleton.	   Axon	   guidance	   is	   the	   process	   by	   which	   growing	   axons	   respond	   to	  
extracellular	   cues	   that	   guide	   them	   towards	   their	   appropriate	   targets.	   Proper	   axon	  
guidance	   is	  vital	   in	  neural	  development	  processes	  such	  as	  neuronal	  cell-­‐migration,	  
axonal	  branching,	  path	   finding,	  and	   fasiculation/defasiculation.	  Our	   laboratory	  has	  
previously	   determined	   the	   crystal	   structure	   of	  MICALs	   FD	   (MICALFD)	   and	   showed	  
that	   it	  uses	  NADPH	  as	  the	  reductant.	  Studies	  showed	  that	  MICALFD	  and	  MICALFD-­‐CH	  
(a	  construct	  containing	  the	  FD	  and	  CH	  domains	  only)	  can	  bind	  and	  oxidize	  Met44	  on	  
actin	   filaments,	   thereby	   affecting	   their	   polymerization	   dynamics.	   CH	   domains	   are	  
typically	   found	   in	  actin-­‐binding	  proteins.	  However,	  modulation	  of	  MICAL	  activities	  
by	   its	   non-­‐redox	   CH	   domain	   is	   poorly	   understood.	   In	   this	   thesis	   work,	   the	  
modulation	   of	   MICAL	   activity	   by	   the	   CH	   domain	   was	   characterized	   structurally,	  
	  
	   iii	  
biochemically,	   and	   thermodynamically.	   The	   crystal	   structure	   of	   MICALFD-­‐CH,	  
determined	  to	  2.9-­‐Å	  resolution,	  reveals	   that	   the	  CH	  domain	  does	  not	   interact	  with	  
the	  active	  site	   in	  the	  FD.	  Furthermore,	   the	  FD	  and	  CH	  domains	  are	  connected	  by	  a	  
disordered	  linker,	  which	  could	  be	  important	  for	  accommodating	  the	  binding	  of	  the	  
FD	  to	  actin.	  Kinetic	  studies	  reveal	  that	  the	  presence	  of	  the	  CH	  domain	  is	  important	  
for	   substrate	   specificity.	   The	   structure	   of	  MICALFD-­‐CH	  was	  used	   to	   build	   a	   possible	  
model	   of	   the	   interaction	   of	   MICAL	   with	   actin.	   Finally,	   molecular	   dynamics	  
simulations	   using	   this	  model	   revealed	   that	   a	   direct	   oxidation	   of	   actin’s	  Met44	   by	  
MICAL	   is	   possible,	   by	   an	   extension	   of	   the	   loop	   containing	   Met44	   of	   actin.	   Taken	  
together,	  this	  thesis	  work	  provides	  valuable	  insight	  into	  the	  means	  by	  which	  the	  CH	  
domain	  of	  MICAL	  modulates	  its	  activity.	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Our	  bodies	   contain	  billions	   of	   neurons	   and	  neural	   connections	   formed	   in	   a	  
very	   complex	   yet	   intricate	   and	   specific	   way.	   	   These	   connections	   are	   formed	   as	   a	  
result	   of	   guidance	   molecules	   interacting	   with	   growing	   neurons,	   directing	   them	  
towards	   or	   away	   from	   a	   certain	   region,	   ultimately	   towards	   their	   target	   tissue.	  
Neurons	   are	   able	   to	   ‘steer’	   because	   upon	   interaction	   with	   attractant	   or	   repellent	  
guidance	  molecules,	  a	   signaling	  cascade	  occurs	   that	   leads	   to	   rearrangement	  of	   the	  
cytoskeletal	   proteins	   (actin,	   microtubules)	   responsible	   for	   maintaining	   structure,	  
rigidity,	   and	   shape	   of	   cells.	   MICAL	   is	   a	   large	   multidomain	   flavoprotein	   whose	  
enzymatic	   monooxygenase	   activity	   is	   required	   for	   neurons’	   ability	   to	   respond	   to	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1.1	   	   Axon	  Guidance	  in	  the	  Nervous	  System	  
	   For	  the	  intricate	  network	  of	  neural	  corrections	  to	  be	  formed	  correctly,	  axons	  
are	  guided	  during	  growth	  to	  their	  targets	  by	  a	  combination	  of	  specific	  attractive	  or	  
repulsive	   extracellular	   cues.	   Neurons	   sense	   their	   external	   environment	   for	   these	  
cues	  through	  their	  highly	  motile	  and	  sensitive	  growth	  cones,	   located	  at	  the	  tip	  of	  a	  
growing	   neuron.	   The	   growth	   cones	   contain	   plasma	  membrane	   receptors	   that	   can	  
interact	  with	   extracellular	   cues,	   and	  when	   such	   an	   interaction	   occurs,	   a	   signaling	  
cascade	   is	   initiated	   inside	   the	   growth	   cone	   that	   leads	   to	   rearrangement	   of	   the	  
cytoskeleton.	   As	   a	   result,	   the	   neuron	   is	   ‘guided’	   in	   response	   to	   the	   extracellular	  
guidance	  cues,	  until	  it	  reaches	  its	  target	  [1-­‐4].	  
	   There	  are	  four	  major	  families	  of	  guidance	  molecules	  that	  have	  been	  identified	  
and	  had	   their	   roles	  established:	  Netrins,	  Slits,	  Semaphorins,	  and	  Ephrins.	  Of	   these,	  
Semaphorins	   are	   the	   most	   well-­‐characterized.	   Semaphorins	   have	   been	   shown	   to	  
function	   as	   repellent	   axon	   guidance	   molecules,	   and	   they	   can	   be	   found	   either	   as	  
transmembrane	  or	  secreted	  (soluble)	  proteins.	  They	  interact	  with	  growth	  cones	  of	  
neurons	   primarily	   through	   Plexin	   receptor	   family	   proteins,	   with	   Neuropilins	  
functioning	  as	  co-­‐receptors	  [3].	  	  	  
	   Upon	   interaction	  with	  a	  semaphorin,	  Plexin	  was	  shown	  to	  recruit	  MICAL	  to	  
its	  cytosolic	  domain	  [5].	  MICAL	  activity	  leads	  to	  cytoskeletal	  rearrangement	  of	  actin	  
microfilaments,	   and	   as	   a	   result	   the	   growth	   cone	   collapses	   in	   the	   region	   where	  
semaphorin	  is	  encountered	  [6,	  7].	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1.1.1	  	   Dynamic	  Modification	  of	  Growth	  Cone	  Shape	  
	   Once	   the	  axon	   is	   formed	   from	  the	  cell	  body	  of	   the	  neuron,	   it	  grows	  along	  a	  
specific	   path	   towards	   target	   tissue.	   The	   shape	   of	   the	   axon	   is	   maintained	   by	  
microtubules.	   At	   the	   growing	   end	   of	   the	   axon	   there	   is	   a	   dynamic	   actin-­‐rich	   hand-­‐
with-­‐finger-­‐like	   structure	   known	   as	   the	   growth	   cone.	   The	   growth	   cone	   has	  many	  
protrusions	   rich	   in	   plasma	   membrane	   receptors	   that	   can	   interact	   with	   external	  
guidance	   cues	   (Figure	   1),	   and	   allow	   sensing	   of	   the	   external	   environment.	   Growth	  
cones	  change	   their	   shape	   (e.g.	   stall,	   collapse,	  extend,	   turn)	   in	   response	   to	  external	  
guidance	  cues.	  Once	  this	  occurs,	  microtubules	   from	  the	  main	  body	  of	   the	  axon	  are	  
allowed	  to	  extend	  into	  the	  growth	  cone,	  in	  the	  desired	  direction	  of	  growth,	  thereby	  
stabilizing	  and	  extending	  the	  axon	  closer	  to	  the	  target	  [8,	  9].	  
	  
1.1.1.1	   Actin	  and	  its	  role	  in	  growth	  cone	  shape	  and	  morphology	  	  
	   Actin	  is	  a	  globular	  374	  amino	  acid	  ~	  43	  kDa	  protein	  that	  can	  form	  a	  double-­‐
helical	   filament	   from	   its	   monomers.	   The	   filaments	   are	   dynamic	   in	   that	   they	  
continuously	  grow	  at	  one	  end	  (plus	  end)	  and	  shrink	  at	  the	  other	  end	  (minus	  end),	  
governed	   by	   the	   nucleotide	   state	   of	   the	   bound	   ATP	  molecule.	   Filaments	   can	   also	  
associate	   into	   parallel/anti-­‐parallel	   bundles	   or	   organize	   into	   a	   mesh	   type	   lattice.	  
Actin	   is	   amongst	   the	   most	   highly	   conserved	   protein	   due	   to	   its	   critical	   role	   in	  
structural	  support	  and	  cell	  movement	  and	  dynamics.	  There	  are	  many	  proteins	  that	  
bind	  monomeric	   (G-­‐actin)	   or	   polymeric	   (F-­‐actin)	   to	   regulate	   actin	   fiber	   dynamics	  
[10].	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Growth	   cones	   are	   actin-­‐rich	   at	   their	   tips,	   and	   F-­‐actin	   is	   required	   for	   shape	  
change.	   They	  possess	   finger-­‐like	   filopodia	   containing	  parallel	   F-­‐actin	   bundles,	   and	  
lamellipodia	   containing	   a	   mesh	   type	   F-­‐actin	   filament	   organization	   (Figure	   1).	  
Signaling	   initiated	   by	   receptors	   in	   growth	   cones	   interacting	   with	   guidance	  
molecules	   induces	   growth	   cone	   shape	   changes	   by	   affecting	   the	   actin	   dynamics.	  
Filament	   assembly	   will	   occur	   at	   the	   sites	   where	   attractive	   guidance	   cues	   are	  
encountered,	  and	  disassembly	  will	  occur	  at	  the	  sites	  where	  repulsive	  guidance	  cues	  
are	  encountered	  [4].	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1.2	   	   Introduction	  to	  MICAL	  proteins	  
	   Initially	   identified	   in	  T-­‐cells	   [11],	  MICAL	  proteins	  have	   also	  been	   identified	  
and	  their	  importance	  in	  control	  of	  cytoskeletal	  dynamics	  characterized	  in	  a	  variety	  
of	   neuronal	   and	   non-­‐neuronal	   cell	   types	   [12-­‐15].	   They	   have	   been	   implicated	   in	  
processes	  such	  as	  axonal	  growth	  cone	  repulsion,	  apoptosis,	  and	  bristle	  development	  
in	   flies.	  MICAL	  proteins	   are	   large	   cytosolic	  proteins	  with	   an	  N-­‐terminal	  non-­‐heme	  
monooxygenase	   that	   contains	   an	   FAD	   cofactor.	   The	   FAD	   co-­‐factor	   forms	   H2O2	   by	  
reducing	  molecular	  oxygen,	   after	  oxidizing	  NADPH	   [16,	  17].	   In	  addition	   to	   the	  FD,	  
MICALs	   contain	   additional	   domains	   known	   to	   be	   involved	   in	   protein-­‐protein	  
interaction.	   These	   domains	   may	   be	   important	   for	   substrate	   recruitment	   and	  
modulation	  of	  activity.	  All	  MICALs	  contain	  a	  CH	  domain,	  typically	  found	  in	  proteins	  
that	   interact	   with	   actin	   [18],	   and	   a	   LIM	   domain	   that	   is	   implicated	   in	   cytoskeletal	  
signaling	  [19].	  Some	  MICALs	  contain	  a	  coiled-­‐coil	  ERM	  domain.	  
	  
1.2.1	   MICAL	  Proteins	  Domain	  Architecture	  
	   MICALs	   are	   found	   in	   invertebrates	   such	   as	  Drosophila	  melanogaster	   all	   the	  
way	   to	   mammals	   such	   as	   Mus	   musculus	   (mouse)	   and	   Homo	   sapiens	   (human).	  
Drosophila	   contains	  one	  MICAL	  protein,	  whereas	  mice	  and	  humans	  have	   three.	  All	  
MICAL-­‐family	   proteins	   contain	   the	   N-­‐terminal	   FD,	   in	   addition	   to	   CH	   and	   LIM	  
domains.	   Most	   of	   them	   have	   the	   C-­‐terminal	   CC	   domain	   [13].	   In	   this	   thesis	   work,	  
constructs	   from	   the	  mouse	   MICAL-­‐1	   protein	   were	   used	   for	   enzyme	   kinetics	   and	  
structure	  determination,	  so	  I	  will	  elaborate	  in	  more	  detail	  the	  domain	  architecture	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of	  MICAL-­‐1	  only.	  All	  subsequent	  mentioning	  of	  MICAL	  will	  be	  in	  reference	  to	  mouse	  
MICAL-­‐1,	  unless	  indicated.	  
The	  N-­‐terminal	  FD	  of	  MICAL	   spans	   the	   first	  484	   residues,	   and	   is	   separated	  
from	   the	   CH	   domain	   (residues	   511-­‐611)	   by	   a	   25-­‐residue	   linker.	   This	   domain	  
arrangement	   and	   sequence	   of	   the	   FD	   and	   CH	   domains	   is	   highly	   conserved	   for	   all	  
MICALs	   [13].	   The	   LIM	   domain	   lies	   between	   residues	   666-­‐761.	   This	   MICAL	   also	  
contains	  a	  CC	  domain	  with	  which	   it	  associates	  with	   the	  cytosolic	  domain	  of	  Plexin	  
upon	  activation	  by	  Semaphorins	  (Figure	  2).	  
	  
1.2.2	   Structure	  of	  MICAL	  domains	  
	   To	   date,	   Nadella	   et	   al.	   and	   Siebold	   et	   al.	   (2005)	   have	   determined	   high-­‐
resolution	  structures	  of	  the	  FD	  of	  mouse	  MICAL-­‐1	  by	  x-­‐ray	  crystallography	  [16,	  20].	  
In	   addition,	   a	   solution	   structure	   of	   an	   isolated	   human	   MICAL-­‐1	   CH	   domain	   was	  
reported,	  and	  its	  unfolding	  was	  studied	  by	  NMR	  [21,	  22].	  	  
	  
1.2.2.1	   Flavin-­‐containing	  Monooxygenase	  Domain	  (FD)	  
	   MICAL’s	   N-­‐terminal	   flavoprotein	   monooxygenase	   domain	   contains	   an	   FAD	  
cofactor	   shown	   to	   oxidize	   NADPH,	   with	   a	   ~70-­‐fold	   preference	   for	   the	  
phosphorylated	   dinucleotide,	   and	   reduce	   molecular	   oxygen	   to	   H2O2	   [16].	   Upon	  
reduction	  by	  NADPH,	  the	  isoalloxazine	  ring	  of	  the	  FAD	  adopts	  an	  “in”	  conformation,	  
similar	  to	  ρ-­‐hydroxybenzoate	  hydroxylase	  (pHBH)	  and	  other	  monooxygenases	  [20].	  
In	   the	   “in”	   conformation	   the	   reduced	   FAD,	   in	   particular	   its	   N5-­‐C4a	   locus,	   is	   less	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solvent	   accessible.	   Structurally,	   the	   FD	   is	   related	   to	   pHBH;	   the	   noteworthy	  
difference	   being	   that	   MICALFD	   has	   a	   much	   more	   open	   active	   site	   and	   could	  
accommodate	   a	   protein	   substrate,	   in	   contrast	   to	   the	   small-­‐molecule	   substrates	   in	  
pHBH.	   The	   redox	   activity	   of	   MICALFD,	   studied	   in	   vitro	   using	   kinetic	   and	  
spectroscopic	   methods,	   showed	   that	   it	   exhibits	   an	   activity	   typical	   of	   a	  
monooxygenase	  [17,	  23].	  
	  
1.2.2.2	   Calponin	  Homology	  (CH)	  Domain	  
	   CH	   domains	   are	   ~100	   residues	   long	   and	   have	   a	   highly	   conserved	  
architecture	  comprised	  mainly	  of	  alpha	  helices.	  They	  carry	  out	  diverse	  functions	  in	  
cytoskeleton	   binding	   and	   signaling.	   Protein	   families	   that	   are	   known	   to	   cross-­‐link	  
actin	   filaments,	   including	   α-­‐actinin	   and	   spectrin,	   interact	   with	   actin	   filaments	   via	  
two	  CH	  domains	  in	  tandem.	  These	  two	  tandem	  CH	  domains	  are	  classified	  as	  type-­‐1	  
and	  type-­‐2.	  Although	  type-­‐3	  CH	  domains	  are	  found	  as	  a	  single	  CH	  domain	  in	  proteins	  
such	   as	   calponin	   and	   IQGAP,	   proteins	   containing	   a	   single	   type-­‐2	   CH	   domain	   also	  
exist	   [24].	   These	  proteins	   include	  MICALs,	   smoothelins,	   and	  RP/EBs.	   The	   solution	  
structure	  of	  human	  MICAL-­‐1	  CH	  domain	   reveals	   that	   it	   exhibits	   a	   similar	   fold	  and	  
architecture	   to	   that	   of	   other	   type-­‐2	   CH	   domains	   [21].	   Its	   structure	   is	   primarily	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1.2.3	   MICAL	   Effects	   on	   Actin	   Dynamics	   in	   Axon	  
Guidance	  
	   Mutant	  Drosophilla	  neurons	  with	  mutations	  in	  the	  MICAL	  gene	  show	  severe	  
axon	  guidance	  defects.	  Furthermore,	  treating	  rat	  dorsal	  root	  ganglia	  (DRG)	  neurons	  
with	  EGCG	  –	  a	  specific	  monoxygenase	  inhibitor	  –	  leaves	  them	  unable	  to	  respond	  to	  
semaphorin	   repulsive	   cues,	   highlighting	   the	   importance	   of	   the	   redox	   activity	   of	  
MICAL	   in	   axon	   guidance	   [5].	   It	   has	   been	   recently	   reported	   that	   MICAL’s	   redox	  
activity	   of	   constructs	   containing	  only	   the	  FD	   alone	  or	   FD	  plus	   the	  CH	  domain	   can	  
alter	   actin	   polymerization	   dynamics,	   by	   specific	   oxidation	   of	   residue	  Met44	   of	   F-­‐
actin,	  leading	  to	  destabilization	  and	  breaking	  up	  of	  actin	  filaments	  [6,	  7].	  Addition	  of	  
F-­‐actin	  to	  either	  Drosophila	  or	  human	  MICALFD-­‐CH	  was	  shown	  to	  stimulate	  its	  redox	  
activity	  in	  vitro,	  as	  measured	  by	  NADPH	  oxidation	  [7,	  17,	  23].	  Interestingly,	  although	  
the	   FD	   alone	   is	   sufficient	   to	   bind	   and	   oxidize	   F-­‐actin	   in	   vitro,	   the	   CH	   domain	   is	  
required	  for	  MICAL	  effects	  on	  actin	  and	  proper	  motor	  axon	  guidance	  in	  vivo	  [6].	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1.3	   	   Thesis	  Objectives	  and	  Summary	  
Although	  it	  is	  known	  that	  the	  CH	  domain	  is	  functionally	  important,	  its	  role	  in	  
the	  MICAL	   function	   is	   unknown.	   Current	   structures	   of	   the	   FD	   and	   CH	   domains	   of	  
MICAL	   are	   of	   individual	   isolated	   MICAL	   domains,	   and	   they	   cannot	   provide	  
information	   on	   how	   the	   FD	   and	   CH	   domains	   interact.	   This	   interaction	   has	   the	  
potential	  of	  controlling	  and	  connecting	   the	  MICAL	  activity	   to	   interactions	  with	   the	  
cytoskeleton.	   The	   aim	   of	   this	   thesis	   is	   to	   investigate	   the	  modulation	   of	   the	   redox	  
activity	   of	  MICAL	   by	   the	   CH	   domain,	   using	   a	   construct	   containing	   the	   FD	   and	   CH	  
domains	  of	  MICAL	  (MICALFD-­‐CH).	  Structural	  (x-­‐ray	  crystallography,	  small-­‐angle	  x-­‐ray	  
scattering),	  biochemical	  (absorbance	  spectroscopy)	  and	  thermodynamic	  (molecular	  
dynamics	   simulations)	   methods	   were	   applied.	   Other	   MICAL	   truncated	   constructs	  
were	   available	   in	   our	   laboratory:	   a	   construct	   containing	   the	   FD	   only	   (MICALFD,	  
residues	  1-­‐484),	  a	  construct	  containing	  the	  FD,	  CH	  and	  LIM	  domains	  (MICALFD-­‐CH-­‐LIM,	  
residues	   1-­‐761),	   a	   construct	   of	   the	   C-­‐terminal	   region	   of	   MICAL	   	   (MICALC-­‐term,	  
residues	  834-­‐1048),	  and	  a	  construct	  of	  full-­‐length	  MICAL	  (fl-­‐MICAL).	  
Kinetic	   experiments	  performed	   to	   follow	   the	   redox	  activity	  of	  MICALFD	  and	  
MICALFD-­‐CH	  (chapter	  2)	  suggest	  that	  the	  CH	  domain	  does	  not	  modify	  the	  active	  site	  of	  
the	  enzyme,	  and	  that	  it	  is	  involved	  in	  substrate	  specificity.	  
In	  chapter	  3,	  the	  crystal	  structure	  of	  MICALFD-­‐CH	  is	  reported.	  Both	  the	  FD	  and	  
CH	  domains	  adopt	  a	  similar	  fold	  to	  that	  seen	  in	  structures	  of	  the	  isolated	  domains.	  
The	   CH	   domain	   contacts	   the	   FD	   far	   from	  where	   NADPH	   is	   predicted	   to	   bind	   and	  
does	  not	  modify	  the	  predicted	  NADPH	  binding	  site,	  in	  agreement	  with	  no	  variation	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of	  the	  KM	  for	  NADPH	  observed	  in	  the	  steady	  state	  kinetics	  results.	  Furthermore,	  the	  
two	   domains	   are	   connected	   by	   a	   flexible	   (disordered)	   linker,	   and	   this	   may	   be	  
important	  for	  optimizing	  binding	  to	  actin.	  
In	   chapter	   4,	   molecular	   dynamics	   simulations	  were	   performed	   in	   order	   to	  
test	  whether	  the	  loop	  of	  actin	  that	  contains	  Met44,	  the	  residue	  oxidized	  by	  MICAL,	  
can	  adopt	  a	  conformation	  where	  it	  is	  in	  close	  proximity	  to	  the	  FAD	  cofactor.	  Results	  
from	  the	  simulations	  show	  that	  Met44	  can	  reach	  a	  position	  within	  the	  FD	  where	  it	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Figure	  1.	  Axon	  guidance.	  
Turning	  of	  an	  axon	  upon	  growth	  cone	  response	  to	  attractant	  and	  repellent	  guidance	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2.	  Enzymatic	  Activity	  of	  MICALFD-­‐CH	  
	  
In	   this	   thesis,	   I	   sought	   to	  determine	   the	  modulation	  of	   the	  redox	  activity	  of	  
the	  FD	  of	  MICAL	  by	   its	  CH	  domain,	  by	   comparing	   the	   redox	  activity	  of	  MICALFD-­‐CH	  
with	  MICALFD.	  Kinetic	  experiments	  were	  used	  to	  follow	  the	  redox	  activity,	  and	  only	  
results	   for	  MICALFD-­‐CH	  will	  be	  presented	   in	   this	   chapter	   (M.U.	  performed	   the	  same	  
experiments	  outlined	  in	  this	  chapter	  with	  the	  MICALFD	  fragment).	  A	  comparison	  of	  
the	  difference	  in	  the	  activities	  between	  MICALFD-­‐CH	  and	  MICALFD	  will	  be	  discussed	  in	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2.1	   	   Introduction	  
	   The	   FD	   of	   MICAL	   is	   a	   monooxygenase	   domain	   containing	   a	   flavin-­‐adenine	  
dinucleotide	  (FAD)	  cofactor,	  structurally	  similar	  to	  pHBH	  [16,	  20].	  The	  noteworthy	  
difference	  between	  MICAL	  and	  pHBH	  is	  the	  presence	  of	  protein-­‐protein	  interaction	  
domains	  in	  MICAL	  (Figure	  2).	  The	  domain	  immediately	  following	  the	  FD	  in	  MICAL	  is	  
the	  CH	  domain.	  CH	  domains	  are	   found	  in	  proteins	  that	  bind	  the	  actin	  cytoskeleton	  
[18],	  but	  the	   function	  of	  MICAL’s	  CH	  domain	  was	  unclear	  prior	  to	  the	  work	   in	  this	  
thesis.	  The	  most	  straightforward	  method	  to	  determine	  the	  effect	  of	  the	  CH	  domain	  
on	  the	  redox	  activity	  of	  the	  FD	  is	  to	  use	  a	  fragment	  of	  MICAL	  containing	  the	  FD	  and	  
CH	  domains	  (MICALFD-­‐CH)	  and	  to	  test	  in	  vitro	  the	  redox	  activity	  of	  this	  fragment,	  and	  
compare	  it	  with	  a	  MICAL	  fragment	  containing	  only	  the	  FD	  (MICALFD).	  	  
	   A	  simple	  kinetic	  assay	  was	  used	  to	  monitor	  the	  redox	  activity	  of	  MICALFD-­‐CH.	  	  
The	  FAD	  in	  the	  FD	  needs	  to	  be	  reduced	  by	  NADPH	  to	  activate	  the	  enzyme.	  Thus,	  in	  a	  
solution	  containing	  MICALFD-­‐CH,	  NADPH,	  and	  a	  substrate,	  NADPH	  is	  consumed,	  with	  
the	   rate	   of	   consumption	   being	   directly	   proportional	   to	   the	   rate	   of	   the	   enzymatic	  
activity.	  NADPH	  has	  an	  absorbance	  peak	  at	  340	  nm	  (ε340	  =	  6.2	  mM-­‐1cm-­‐1),	  while	  its	  
product	  NADP+	  does	  not	  absorb	  at	  that	  wavelength.	  It	  is	  this	  attribute	  of	  NADPH	  that	  
allows	  us	  to	  follow	  the	  reaction	  in	  real-­‐time	  by	  ultraviolet	  (UV)	  spectroscopy.	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2.2	   	   Results	  
All	  enzyme	  kinetics	  experiments	  were	  carried	  out	  using	  either	  O2	  alone	  or	  O2	  
and	   actin	   as	   substrates	   and	   NADPH	   as	   the	   source	   of	   reducing	   equivalents.	   The	  
reaction	   was	   followed	   at	   340	   nm	   at	   298K	   with	   a	   JASCO-­‐v560	   UV-­‐Visible	  
Spectrophotometer.	  Assays	  were	  performed	  in	  110	  µl	  of	  a	  solution,	  with	  the	  buffer	  
for	   each	   experiment	  mentioned	   below.	   To	   estimate	  Michaelis-­‐Menten	   parameters	  
KM	  and	  kcat,	  NADPH	  was	  added	  at	  concentrations	  from	  10	  to	  180	  µM,	  and	  the	  initial	  
rates	   from	   the	   first	   60	   seconds	   of	   the	   reaction	   were	   fit	   to	   the	   Michaelis-­‐Menten	  
equation	  using	  gnuplot	  non-­‐linear	  curve	  fitting:	  
€ 
rate = Vmax S[ ]
Km + S[ ]
	  	   	   	   	   	   (2.1)	  
	  
where	   the	   rate	   is	   that	   of	  NADPH	  consumption	  by	  MICALFD-­‐CH,	   Vmax	   is	   the	  maximal	  
rate	  of	   the	  reaction,	  and	  KM	   is	   the	  substrate	  concentration	   [S]	  at	  which	  rate	  of	   the	  
reaction	  is	  one	  half	  of	  Vmax.	  In	  the	  experiments	  outlined	  below,	  [S]	  is	  [NADPH].	  
	  
2.2.1	   Redox	  activity	  
	   The	   experiment	   was	   carried	   out	   in	   a	   buffer	   previously	   determined	   in	   our	  
laboratory	  to	  be	  optimal	  for	  following	  MICAL	  redox	  activity:	  10	  mM	  Tris-­‐HCl	  pH	  7.0,	  
20	  mM	  NaCl	   [16].	   10	  µl	   of	   600	  nM	  of	  MICALFD-­‐CH	  was	  used	   in	   each	  measurement,	  
with	  100	  µl	  of	  vaying	  NADPH	  concentrations.	  Figure	  3	  shows	  a	  typical	  dataset,	  with	  
a	   kcat	   of	   1.1	   ±	   0.03	   s-­‐1	   and	   a	   KM	   of	   5.6	   ±	   1.0	   µM.	   This	   is	   on	   the	   same	   order	   of	  
magnitude	  to	  that	  of	  MICALFD:	  kcat	  of	  1.8	  ±	  0.1	  s-­‐1,	  and	  a	  KM	  of	  3.0	  ±	  0.7	  µM.	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   These	  results	  indicate	  that	  the	  presence	  of	  the	  CH	  domain	  does	  not	  affect	  the	  
binding	  of	  NADPH	  to	  the	  active	  site	  in	  the	  FD,	  as	  both	  MICALFD	  and	  MICALFD-­‐CH	  have	  
a	   similar	   KM.	   Furthermore,	   the	   fact	   that	   both	   these	   fragments	   share	   a	   similar	   kcat	  
suggests	   that	   the	   active	   site	   is	   unperturbed	   and	   has	   a	   similar	   conformation	   in	  
MICALFD-­‐CH	  compared	  with	  MICALFD.	  
	  
2.2.2	   Inhibition	  by	  MICALC-­‐term	  
Previous	   studies	   of	   MICAL	   truncation	   mutants	   in	   vivo	   provided	   indication	  
that	   the	   C-­‐term	   region	   (immediately	   following	   the	   LIM	   domain,	   aa	   761-­‐1048)	   of	  
MICAL	  can	  inhibit	  the	  redox	  activity	  [25,	  26].	  The	  intra-­‐molecular	  control	  of	  redox	  
activity	  is	  important	  for	  two	  main	  reasons.	  First,	  MICAL	  can	  reduce	  O2	  and	  produce	  
H2O2	  using	  NADPH	   reducing	   equivalents	   [16].	  Although	  H2O2	   itself	   is	   not	   a	   strong	  
oxidant,	  hydroxyl	  radicals	  (reactive	  oxygen	  species	  –	  ROS)	  can	  be	  generated	  from	  it	  
upon	  photolysis,	   interaction	  with	  reactive	  metals	  (e.g.	   Iron),	  or	  activation	  by	  thiols	  
of	  cysteine	  (methionine)	  side	  chains.	  ROS	  are	  very	  reactive	  and	  can	  cause	  oxidative	  
damage	   to	   macromolecules	   that	   could	   lead	   to	   harmful	   effects	   to	   the	   cell	   even	   at	  
moderate	   concentrations	   (~100	   µM)	   [27].	   Second,	   MICAL	   directly	   oxidizes	   actin	  
filaments	   via	   its	   monooxygenase	   activity,	   leading	   to	   filament	   disassembly,	   upon	  
activation	   by	   Semaphorin-­‐Plexin	   signaling	   [5,	   7].	   As	   a	   result,	   the	   growth	   cone	  
collapses	   in	   the	   region	   where	   the	   repellent	   semaphorin	   signal	   is	   encountered.	   If	  
MICAL	  cannot	  be	  controlled	  by	  the	  signaling	  pathway,	  it	  could	  lead	  to	  axon	  guidance	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defects	   (as	   a	   result	   of	   not	   responding	   appropriately	   to	   the	   attractant	   or	   repellent	  
guidance	  cues)	  in	  those	  neurons.	  	  
	   The	  effect	  of	  the	  C-­‐term	  of	  MICAL	  on	  the	  redox	  activity	  was	  tested	  with	  the	  
steady-­‐state	   kinetic	   assay,	   by	   addition	   of	   a	   MICAL	   fragment	   containing	   the	   C-­‐
terminal	   residues	   824-­‐1048	   (MICALC-­‐term)	   to	   MICALFD-­‐CH.	   The	   same	   experimental	  
conditions	   were	   used	   as	   in	   the	   previous	   section,	   varying	   the	   concentration	   of	  
MICALC-­‐term.	  
	   Results	  show	  that	  addition	  of	  MICALC-­‐term	  to	  MICALFD-­‐CH	  leads	  to	  a	  decrease	  in	  
the	   redox	   activity;	   the	   same	   thing	   is	   observed	   for	   MICALFD.	   It	   was	   observed	   that	  
addition	   of	   MICALC-­‐term	   decreases	   the	   Vmax	   but	   not	   the	   KM;	   indicative	   of	   non-­‐
competitive	   inhibition	   (Figure	   3).	   The	   data	   were	   fit	   to	   the	   modified	   Michaelis-­‐
Menten	  equation	  for	  non-­‐competitive	  inhibition	  to	  estimate	  the	  inhibition	  constant	  
Ki.	  MICALFD	  and	  MICALFD-­‐CH	  have	  a	  similar	  Ki	  of	  inhibition	  by	  MICALC-­‐term:	  138	  ±	  18	  
µM	  and	  128	  ±	  8.6	  µM	  for	  the	  two	  fragments,	  respectively.	  	  
	  
2.2.3	   Activation	  by	  actin	  
	   Prior	  to	  the	  experiments	  in	  this	  section	  being	  conducted,	   it	  was	  known	  that	  
actin	  is	  a	  substrate	  of	  MICAL	  and	  that	  MICAL	  can	  modify	  actin	  filaments,	  leading	  to	  
their	   disassembly	   [7].	   However,	   the	   kinetic	   parameters	   of	   this	   oxidation	   were	  
unknown.	  	  
To	   determine	   these	   parameters,	   the	   kinetic	   assay	   following	   NADPH	  
consumption	   was	   carried	   out	   as	   in	   2.2.1,	   for	   different	   concentrations	   of	   globular	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actin	  (G-­‐actin,	  monomer)	  or	  filamentous	  actin	  (F-­‐actin,	  polymer).	  Actin	  from	  Rabbit	  
Skeletal	   Muscle	   was	   used	   (Cytoskeleton	   Inc.,	   cat.	   #	   AKL99),	   which	   was	   initially	  
reconstituted	  to	  100	  µl	  at	  a	  concentration	  of	  222	  µM.	  
	  	   For	  G-­‐actin	  experiments,	  buffer	  G	  was	  used	  (5	  mM	  Tris-­‐HCl	  pH	  8.0,	  0.2	  mM	  
CaCl2).	  The	  222	  µM	  actin	  was	  diluted	  to	  22	  µM	  in	  buffer	  G,	   incubated	  on	  ice	  for	  30	  
mins,	  and	  ultracentrifuged	  100,000	  g	  for	  30	  minutes	  at	  4˚C	  to	  pellet	  any	  nuclei;	  the	  
supernatant	  was	  carefully	  removed	  for	  use	  in	  the	  experiments.	  	  
The	  experiments	  with	  F-­‐actin	  were	  also	   in	  buffer	  G,	  with	  the	  addition	  of	  50	  
mM	  KCl,	  2	  mM	  MgCl2,	  1	  mM	  ATP	  to	  maintain	  polymerization	  conditions.	  The	  222	  µM	  
actin	  was	  diluted	  to	  22	  µM	  in	  the	  aforementioned	  buffer,	  and	  allowed	  to	  polymerize	  
for	  30	  mins	  at	  room	  temperature,	  before	  use.	  
	  Addition	  of	  G-­‐actin	  or	  F-­‐actin	  to	  the	  MICALFD-­‐CH	  and	  NADPH	  reaction	  shows	  
an	  increase	  the	  kcat	  on	  the	  order	  of	  5-­‐fold,	  compared	  with	  no	  actin	  (Figure	  4,	  5).	  This	  
increase	   is	  similar	  whether	  G-­‐actin	  or	  F-­‐actin	  was	  added.	  This	   is	  not	   the	  case	  with	  
MICALFD,	  where	  only	  a	  small	  increase	  in	  kcat	  is	  observed.	  
	   This	   result	   suggests	   that	   the	   CH	   domain	   is	   responsible	   for	   substrate	  
specificity,	  because	  only	  when	  it	  is	  present	  in	  MICAL	  the	  redox	  activity	  is	  enhanced	  
by	  actin.	   In	   the	  absence	  of	  actin	  and	  with	  NADPH	  present,	   the	  enzyme	  produces	  1	  
equivalent	   of	   H2O2	   per	   molecule	   of	   NADPH.	   To	   test	   whether	   the	   reducing	  
equivalents	   from	   NADPH	   are	   going	   directly	   to	   actin	   or	   towards	   bulk	   H2O2	  
production	  when	   actin	   is	   added,	   a	   preliminary	   experiment	  was	   performed	  where	  
the	  total	  [H2O2]	  was	  measured	  at	  different	  F-­‐actin	  concentrations	  using	  the	  Amplex	  
Red	  Hydrogen	  Peroxide/Peroxidase	  Assay	  (A22188,	  Sigma)	  (ε560	  =	  44.3	  mM-­‐1cm-­‐1).	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The	   experiment	   shows	   a	   decrease	   in	   total	  H2O2	   produced	  upon	   adding	   increasing	  
concentrations	  of	  F-­‐actin	  (Figure	  6).	  To	  discount	  the	  effect	  of	  bulk	  H2O2	  oxidation	  of	  
actin	   non-­‐enzymatically,	   a	   control	   experiment	   was	   carried	   out	   where	   H2O2	   was	  
added	   instead	   of	   NADPH	   (Figure	   6).	   Taken	   together,	   the	   experiment	   shows	   a	  
decrease	  in	  H2O2	  upon	  addition	  of	  F-­‐actin:	  2	  molecules	  less	  per	  molecule	  of	  F-­‐actin	  
to	   be	   precise.	   This	   suggests	   that	   the	   enhanced	   activity,	   and	   reducing	   equivalents	  
from	  NADPH,	  go	  directly	  towards	  modifying	  actin.	  
	  
2.2.4	   Effect	  of	  NaCl	  
Ionic	  strength	  in	  the	  cytosol	  can	  vary,	  so	  to	  test	  the	  effect	  of	  ionic	  strength	  on	  
the	  redox	  activity	  of	  MICAL,	  NaCl	  was	  added	  to	  a	  reaction	  containing	  MICALFD-­‐CH	  and	  
varying	  NADPH	  concentrations.	  
The	  result	  shows	  that	  the	  major	  effect	  is	  on	  the	  KM	  for	  NADPH:	  KM	  increases	  
with	   increasing	   NaCl	   concentration	   (Figure	   7).	   The	   same	   result	   is	   observed	   for	  
MICALFD.	   This	  means	   that	  NaCl	   is	   competing	  with	  NADPH	   for	  binding,	   or	   in	   other	  
words,	  NaCl	  competes	  for	  the	  same	  binding	  site	  or	  region	  of	  MICAL	  as	  NADPH.	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2.3	   	   Conclusions	  and	  Discussion	  
	   The	  described	  experiments	  provide	  important	  clues	  about	  the	  possible	  roles	  
of	   the	   CH	   domain.	   First,	   given	   that	   MICALFD	   and	   MICALFD-­‐CH	   have	   similar	   redox	  
activity	  with	  respect	  to	  NADPH	  consumption,	  it	  suggests	  that	  the	  presence	  of	  the	  CH	  
domain	  does	  not	  change	  the	  active	  site	  of	  the	  FD.	  Furthermore,	  since	  MICALFD	  and	  
MICALFD-­‐CH	  have	  similar	  values	  of	  KM	  for	  NADPH,	  the	  conformation	  of	  the	  active	  site	  
of	  the	  FD	  in	  MICALFD	  and	  MICALFD-­‐CH	  is	  the	  same.	  
	   When	  no	  actin	   is	  present	   in	   the	   reaction	  with	  MICALFD	  or	  MICALFD-­‐CH,	   their	  
respective	  kcats	   of	  NADPH	  consumption	  are	   similar.	  Upon	  addition	  of	  F-­‐actin,	   only	  
MICALFD-­‐CH	  shows	  an	   increase	   in	  kcat,	  but	  not	  MICALFD.	  MICALFD-­‐CH	  binds	   to	  F-­‐actin	  
with	   low	   µM	   affinity,	   as	   determined	   by	   a	   co-­‐sedimentation	   approach	   (Figure	   8).	  
Taken	  together,	  this	  strongly	  suggests	  that	  the	  CH	  domain	  plays	  a	  role	  in	  substrate	  
recognition	  and	  specificity,	  such	  that	  the	  redox	  activity	  of	  the	  enzyme	  increases	  only	  
when	   the	   substrate	   (F-­‐actin	   or	   G-­‐actin)	   is	   present.	   At	   the	   time	   of	   writing	   this	  
dissertation,	  a	  study	  was	  reported	  where	  authors	  observed	  a	  similar	  enhancement	  
for	  human	  MICALFD-­‐CH	  in	  presence	  of	  F-­‐actin	  [28].	  
The	  enhancement	  of	  MICALFD-­‐CH	  redox	  activity	  observed	  (with	  F-­‐actin	  and/or	  
G-­‐actin)	  here	  is	  not	  in	  agreement	  with	  other	  studies	  [7,	  17,	  23].	  In	  the	  presence	  of	  F-­‐
actin	  but	  not	  G-­‐actin,	  Zuchinni	  et	  al.	  and	  Mcdonald	  et	  al.	  report	  an	  enhancement	  in	  
the	   activity	   of	   human	   MICAL-­‐1	   and	   MICAL-­‐2	   activity,	   respectively.	   They	   used	  
MICALFD	  constructs	  that	  lack	  the	  CH	  and	  the	  rest	  of	  the	  MICAL	  domains.	  This	  may	  be	  
due	  to	  the	  requirement	  of	  MICAL	  for	  the	  CH	  domain	  to	  be	  able	  to	  recognize	  G-­‐actin	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as	  a	  substrate.	  Hung	  et	  al.	  use	  a	  Drosophilla	  MICALFD-­‐CH	  construct	  and	  also	  show	  that,	  
with	   F-­‐actin	   but	   not	   G-­‐actin,	   the	   NADPH	   consumption	   by	   MICAL	   is	   enhanced.	   A	  
possible	   explanation	   is	   that	  Drosophilla	   MICAL	   and	  Drosophilla	   actin	   used	   in	   that	  
study	  may	  behave	  differently	  from	  mammalian	  (mouse	  MICAL-­‐1)	  used	  in	  this	  study.	  	  
Less	  bulk	  H2O2	  is	  produced	  by	  MICALFD-­‐CH	  in	  the	  presence	  of	  F-­‐actin,	  and	  this	  
suggests	   that	   the	   oxygen	   atoms	   of	   the	   reduced	   C4a-­‐hydroperoxidate	   FAD	  
intermediate	  are	  used	  to	  oxidize	  the	  actin	  filaments.	  It	  remains	  to	  be	  tested	  whether	  
this	   modification	   is	   a	   direct	   oxidation,	   or	   as	   a	   result	   of	   increased	   local	   H2O2	  
concentration	  near	  the	  actin	  filament.	  	  
The	   fact	   that	  NaCl	  has	   a	   similar	   effect	   on	  MICALFD	   and	  MICALFD-­‐CH,	   namely,	  
that	   it	   increases	   the	  KM	   for	  NADPH	   consumption,	   further	   supports	   the	   conclusion	  
that	  the	  FD	  in	  MICALFD	  and	  MICALFD-­‐CH	  shares	  the	  same	  conformation.	  
	  
	  





Figure	  3.	  MICALFD-­‐CH	  inhibition	  by	  MICALC-­‐term.	  	  
CTD	   –	   C-­‐terminal	   domain	   of	   MICAL.	   Concentrations	   of	   MICALC-­‐term	   added	   are	  



















	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  8.	  MICALFD-­‐CH	  binding	  to	  F-­‐actin.	  
4	  µM	  of	  actin	  was	  first	  polymerized	  (see	  2.2.3),	  incubated	  with	  0-­‐31	  µM	  of	  MICALFD-­‐
CH	  at	  room	  temperature	  for	  1	  hr,	  and	  ultracentrifuged	  at	  100,000	  xg	  for	  30	  minutes.	  
Supernatants	  (S)	  were	  carefully	  removed	  and	  added	  to	  2X	  Laemmlli	  sample	  buffer	  
for	  loading	  on	  SDS-­‐PAGE	  gel.	  The	  pellet	  (P)	  was	  resuspended	  with	  the	  actin	  buffer,	  
incubated	  at	  room	  temperature	  for	  10	  minutes,	  and	  added	  to	  a	  2X	  Laemmlli	  sample	  
buffer	   for	   loading	   on	   SDS-­‐PAGE	   gel.	   (A)	   Quantification	   of	   the	   intensities	   of	   the	  
MICALFD-­‐CH	  bands	  in	  the	  supernatant	  and	  the	  pellet	  from	  the	  SDS-­‐PAGE	  gel	  (B)	  was	  
performed	  using	  the	  ImageJ	  software	  [29],	  and	  plotted	  using	  gnuplot	  software.	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[MICALFD-­‐CH]	  (µM)	  :	  	  	  	  	  	  	  	  	  0.95	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.9	  	  	  	  	  	  	  	  	  	  	  	  	  3.8	  	  	  	  	  	  	  	  	  	  	  	  	  7.7	  	  	  	  	  	  	  	  	  	  	  	  	  	  15.4	  	  	  	  	  	  	  	  30.8	  
KD	  =	  9.5	  ±	  2.5	  µM	  
	  
Bmax	  =	  2.6	  ±	  0.4	  µM	  
	  
	   28	  
	  
	  
3.	  Structural	  Characterization	  of	  MICALFD-­‐CH	  
	  
The	  kinetic	  studies	  performed	  with	  MICALFD-­‐CH	  (chapter	  2)	  suggest	  that	  even	  
though	  the	  CH	  domain	  does	  not	   interact	  with	  the	  active	  site	   in	  the	  FD,	   it	  enhances	  
the	  redox	  activity	  in	  the	  presence	  of	  actin.	  To	  gain	  a	  more	  detailed	  understanding	  of	  
how	  this	  occurs,	  a	  major	  effort	  in	  this	  thesis	  work	  was	  devoted	  to	  crystallization	  and	  
structure	  determination	  of	  MICALFD-­‐CH.	  Only	  with	  an	  atomic-­‐resolution	  structure	  of	  
the	   FD	   and	   the	   CH	   domains	   contained	   in	   a	   single	   polypeptide	   chain	   can	   one	   gain	  
insight	  into	  the	  influence	  of	  the	  CH	  domain	  on	  the	  activity	  of	  the	  FD.	  The	  structure	  of	  
MICALFD-­‐CH	   reveals	   that	   the	  CH	  domain	   contacts	   the	  FD	   far	   from	  where	  NADPH	   is	  
predicted	   to	   bind,	   in	   agreement	   with	   the	   interpretation	   of	   the	   kinetics	   results.	  
Furthermore,	   it	   reveals	   that	   a	   flexible	   linker	   (disordered	   in	   the	   crystal	   structure)	  
connects	   the	   two	   domains,	   and	   this	   flexibility	   may	   be	   important	   for	   optimizing	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3.1	   	   Introduction	  
Growing	  axons	  are	  guided	  to	  their	  appropriate	  target	  tissues	  by	  extracellular	  
cues	  (Figure	  1).	  These	  guidance	  cues	  are	  essential	  for	  appropriate	  neuronal	  growth	  
and	   development,	   rewiring,	   fasciculation/defasiculation,	   and	   nerve	   regeneration	  
after	   injury	   [3].	   Semaphorins,	   the	   best	   characterized	   class	   of	   external	   repellent	  
guidance	  molecules,	  interact	  with	  Plexin	  and	  neuropilin	  receptors	  on	  axonal	  growth	  
cones	   [30,	   31].	   Upon	   interaction	   with	   extracellular	   semaphorins,	   Plexin	   recruits	  
MICAL	   (Molecule	   Interacting	  with	   CasL)	   to	   its	   cytosolic	   domain,	   and	   this	   leads	   to	  
growth	   cone	   collapse	   as	   a	   result	   of	   reorganization	   of	   the	   cytoskeleton	   caused	   by	  
MICAL	  activity	  [5-­‐7].	  
	   MICAL	  is	  unique	  in	  that	  it	  combines	  a	  catalytic	  monooxygenase	  domain	  with	  
three	  domains	  known	  to	  be	   involved	   in	  protein-­‐protein	   interaction,	  which	  may	  be	  
important	   for	   recruitment	  of	   substrates	   and	  modulation	  of	   its	   activity	   [13].	   These	  
include	  an	   immediately	   adjacent	  CH	  domain	   that	   is	   usually	   found	   in	   actin-­‐binding	  
proteins.	  Modulation	  of	  MICAL	  activities	  by	  its	  non-­‐redox	  domains	  is	  crucial	  since	  its	  
redox	  activity	  can	  directly	  oxidize	  actin	  filaments	  leading	  to	  their	  depolymerization,	  
and	  must	  be	  controlled	  so	  that	  it	  is	  on	  or	  off	  at	  the	  right	  times.	  	  
To	   gain	   insight	   into	   modulation	   by	   the	   CH	   domain,	   steady-­‐state	   kinetic	  
experiments	   were	   initially	   carried	   out	   in	   the	   absence	   and	   presence	   of	   actin	  
(described	  in	  chapter	  2).	  The	  results	  show	  that	  the	  CH	  domain	  could	  be	  acting	  as	  a	  
substrate	   specificity	   factor	   by	   enhancing	   the	   activity	   of	   the	   FD	   only	   when	   the	  
substrate	   (actin)	   is	   present.	   The	   structural	   determinants	   for	   this	   modulation	   are	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unclear,	   however.	   Given	   that	   the	   only	   available	   structures	   are	   of	   isolated	   MICAL	  
domains,	   the	   work	   described	   in	   this	   chapter	   was	   dedicated	   to	   structural	  
determination	   and	   characterization	   of	   a	   fragment	   containing	  MICAL’s	   FD	   and	   CH	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3.2	   	   Results	  
	  
3.2.1	   Expression	  and	  Purification	  of	  MICALFD-­‐CH	  
Cloning	  
A	  plasmid	  containing	  DNA	  coding	  for	  MICAL-­‐1	  from	  mouse	  (codon-­‐optimized	  
for	  expression	   in	  Escherichia	  coli	  –	  Genescript	   Inc.)	  residues	  2-­‐615	  (containing	  the	  
Q78K	  mutation	  to	  remove	  an	  endogenous	  protease	  site)	  was	  cloned	  onto	  a	  pET28a	  
expression	  vector	  containing	  an	  N-­‐terminal	  His-­‐tag	  with	  an	  engineered	  N-­‐terminal	  
Tobacco	  etch	  virus	  (TEV)	  protease	  site,	  and	  used	  to	  transform	  Escherichia	  coli	  BL21.	  	  
	  
Protein	  expression	  and	  purification	  
After	   induction	   by	   addition	   of	   0.2	  mM	  β-­‐D-­‐1-­‐thiogalactopyranoside	   (IPTG),	  
cells	   were	   grown	   for	   15	   hours	   at	   17°C	   in	   LB	   media	   before	   harvesting	   by	  
centrifugation	   and	   freezing	   the	   pellets	   in	   -­‐80˚C.	   Frozen	   pellets	  were	   resuspend	   in	  
lysis	  buffer	  containing	  50	  mM	  Tris-­‐HCl	  pH	  7.0,	  140	  mM	  NaCl,	  10	  mM	  Imidazole,	  0.1	  
%	  Tween-­‐20,	  5	  mM	  MgCl2,	  2	  mM	  β-­‐mercaptoethanol	  (BME),	  5	  mM	  Benzamidine,	  and	  
10	   %	   v/v	   glycerol.	   Cells	   were	   broken	   via	   microfluidization,	   and	   the	   lysate	   was	  
centrifuged	  at	  23,000	  xg	  for	  60	  minutes.	  The	  supernatant	  was	  collected	  and	  filtered	  
in	   a	   0.22	   micron	   Stericup	   filter	   (Millipore)	   before	   loading	   on	   an	   AKTA	   FPLC	  
machine.	   The	   protein	   was	   purified	   by	   Ni-­‐Sepharose	   affinity	   chromatography	   (His	  
trap	  column,	  5	  ml,	  GE)	  with	  a	  gradient	  of	  50	  mM	  Tris-­‐HCl	  pH	  7.0,	  140	  mM	  NaCl,	  10-­‐
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500	  mM	  imidazole.	  The	  eluted	  protein	  was	  dialyzed	  against	  50	  mM	  Tris-­‐HCl	  pH	  7.0,	  
and	  200	  mM	  Glycine,	  and	  digested	  overnight	  with	  TEV	  protease	  to	  remove	  the	  His-­‐
tag.	   The	   cleaved	   product	   was	   purified	   by	   using	   a	   Source	   15S	   cation	   exchange	  
column,	   eluting	  with	  50	  mM	  Tris-­‐HCl	  pH	  7.0,	   and	  0-­‐1	  M	  NaCl	   gradient	   (Figure	  9).	  
The	  final	  yield	  was	  ~	  3	  mg	  per	  liter	  of	  culture.	  After	  dialysis	  to	  buffer	  exchange	  to	  50	  
mM	   Tris-­‐HCl	   pH	   7.0,	   200	  mM	  NaCl,	  MICALFD-­‐CH	   was	   concentrated	   to	   ~	   25	  mg/ml	  
using	  a	  3	  kDa	  MWCO	  ultrafiltration	  device	  (GE	  Healthcare),	  before	  storage	  at	  -­‐80˚C.	  
MICALFD-­‐CH	   is	  unstable	  without	   the	  presence	  of	   salt	  and	  attempting	   to	  concentrate	  
the	  protein	  in	  Tris	  buffer	  lacking	  NaCl	  causes	  precipitation	  of	  the	  protein.	  
	  
3.2.2	   Crystallization	  of	  MICALFD-­‐CH	  
Differential	  scanning	  fluorimetry	  
	   Before	   initiating	   crystallization	   trials,	   the	   thermal	   stability	   of	   purified	  
MICALFD-­‐CH	   was	   subject	   to	   differential	   scanning	   fluorimetry	   analysis	   [32].	   This	  
experiment	  measures	  the	  thermal	  stability	  of	  MICALFD-­‐CH	  in	  varying	  buffer,	  pH,	  and	  
salt	   conditions.	   Increased	   thermal	   stability	   of	   the	   protein	   could	   enhance	   the	  
probability	   of	   crystallization.	  Results	   are	   shown	   in	   a	  qualitative	  manner	  using	   the	  
ThermoQ	  software	  (Figure	  10).	  	  
	  
Crystallization	  trials	  
	   From	   the	   results	   of	   the	   differential	   scanning	   fluorimetry,	   I	   decided	   to	   use	  
MES	   pH	   6.0	   buffer	   for	   protein	   storage	   prior	   to	   screening	   for	   crystallization	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conditions.	  Initial	  screening	  attempts	  (1	  µl	  of	  protein	  solution	  combined	  with	  1	  µl	  of	  
reservoir	  solution	  and	  equilibrated	  against	  500	  µl	  of	  reservoir	  solution)	  were	  based	  
on	   screening	   around	   the	   crystallization	   condition	   for	   MICALFD	   (PDB	   2BRA),	  
containing	   PEG	  2000	  MME	   and	   sodium	   acetate	   pH	  4.6,	   in	   a	   hanging-­‐drop	   24-­‐well	  
format.	   Some	   phase	   separation	   and	   microcrystals	   were	   observed,	   but	   nothing	  
suitable	  for	  data	  collection.	  Trials	  in	  these	  same	  conditions	  with	  the	  protein	  being	  in	  
sodium	   citrate	   buffer	   pH	   5.0	   instead	   of	   MES	   buffer	   pH	   6.0	   gave	   the	   first	   “proto-­‐
crystals”	   of	   MICALFD-­‐CH	   (Figure	   11).	   Sodium	   citrate	   buffer	   pH	   5.0	   also	   enhanced	  
thermal	  stability	  of	  MICALFD-­‐CH	  similar	  to	  the	  MES	  buffer.	  The	  first	  sign	  of	  “needles”	  
was	  observed	  by	  screening	  with	  the	  same	  conditions	  [21	  %	  PEG	  2000	  MME,	  0.1	  M	  
sodium	   acetate	   pH	   5.0]	   but	   in	   a	   sitting-­‐drop	   vapor	   diffusion	   setup	   as	   opposed	   to	  
hanging	  drop	  (Figure	  11).	  	  
	  
Final	  conditions	  and	  microseeding	  
The	  “needles”	  were	  optimized	  to	  a	  “large	  cluster	  of	  needles”	  by	  using	  HEPES	  
buffer	   pH	   7.5	   was	   used	   instead	   of	   sodium	   acetate	   pH	   5.0	   in	   the	   crystallization	  
condition	  [20-­‐22	  %	  PEG	  2000	  MME,	  0.1	  M	  HEPES	  pH	  7.5]	  (Figure	  11).	  This	  cluster	  of	  
needles	  was	  used	  for	  microseeding,	  varying	  the	  dilution	  of	  the	  seeds	  in	  the	  mother	  
liquor,	  until	  “cluster	  of	  rods”	  grew	  where	  single	  rod-­‐shaped	  crystals	  could	  be	  picked	  
and	  mounted	  for	  data	  collection.	  The	  “large	  cluster	  of	  needles”	  is	  not	  reproducible,	  
and	  to	  grow	  more	  MICALFD-­‐CH	  crystals	  microseeding	  from	  a	  drop	  that	  contains	  some	  
needles/rods	  is	  required.	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In	   summary,	   for	   crystalization	   of	   MICALFD-­‐CH,	   1	   µl	   of	   protein	   solution	   [25	  
mg/ml	  in	  100	  mM	  sodium	  citrate	  pH	  5.0,	  200	  mM	  NaCl]	  was	  combined	  with	  1	  µl	  of	  
reservoir	   solution	   [100	   mM	   HEPES	   pH	   7.0,	   20	   %	   PEG	   2000	   MME]	   containing	  
microseeds	  and	  equilibrated	  against	  500	  µl	  of	  reservoir	  solution.	  Crystals	  grew	  in	  24	  
hours	  at	  20̊C.	  
	  
3.2.3	   Structure	  Determination	  of	  MICALFD-­‐CH	  
	  
3.2.3.1	   Native	  data	  colection	  from	  one	  crystal	  (crystal	  1)	  
	   For	   native	   data	   colection,	   a	   single	   rod	   in	   a	   bunch	   of	   rods	   was	   isolated	   and	  
mounted	  on	  a	  nylon	  loop	  (Hampton	  Research).	  Prior	  to	  mounting,	  the	  thin	  film	  that	  
forms	   on	   the	   surface	   of	   the	   drop	   containing	   the	   crystals	   needed	   to	   be	   removed	  
gently	   with	   a	   loop	   or	   needle.	   The	   crystal	   was	   washed	   in	   a	   drop	   containing	   the	  
crystalization	   condition,	   and	   once	   more	   in	   a	   similar	   drop	   but	   with	   10	   %	   glycerol	  
added	  for	  cryoprotection.	  Crystals	  were	  flash-­‐frozen	  in	  liquid	  nitrogen.	  
MICALFD-­‐CH	   crystals	   difracted	   up	   to	   moderate	  2.9	   Å	   resolution	   on	   a	   Saturn	  
944+	   CCD	   detector	   (Rigaku	   Americas	   Corporation,	   The	   Woodlands,	   TX)	   with	   in-­‐
house	   light	   source	   FR-­‐E+	   Super-­‐BrightTM	   generator	   (Rigaku	   Americas	   Corporation,	  
The	   Woodlands,	   TX)	   equipped	   with	   VariMAX	   mirrors	   and	   a	   copper	   rotating	   anode	  
generating	  X-­‐rays	  with	  wavelength	  of	  1.5418	  Å.	  
Crystals	  belong	  to	  the	  P21	  space	  group	  with	  cel	  dimensions:	  a	  =	  64.5	  Å,	  b	  =	  
49.9	   Å,	   c	   =	   94.7	   Å,	   ̧	   α	   =	   γ	   =	   90.0	   ̊,	   β	   =	   107.9	   ̊.	   They	   contained	   one	   MICALFD-­‐CH	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molecule	   per	   asymmetric	   unit.	   Native	   data	   were	   reduced	   and	   processed	   with	  
HKL2000	  (HKL	  Research	  Inc.).	  Data	  collection	  statistics	  are	  shown	  in	  Table	  3.1.	  
	  
3.2.3.2	   Phase	  Determination	  
	   To	  obtain	  the	  three-­‐dimensional	  structure	  of	  the	  protein	  from	  the	  diffraction	  
data,	   phase	   angles	   must	   be	   determined	   (see	   chapter	   5	   for	   background	   of	   the	  
technique).	  MICALFD-­‐CH	   spans	   the	   first	   615	   amino	   acids	   of	   the	  MICAL	  protein,	   and	  
since	   the	   crystal	   structure	   of	  MICALFD	   (PDB	   2BRA)	   previously	   determined	   in	   our	  
laboratory	  spans	  the	  first	  484	  amino	  acids	  i.e.	  ~	  80	  %	  and	  is	  the	  exact	  same	  FD,	  the	  
phases	  were	  determined	  by	   the	  molecular	   replacement	  method	  with	   the	  program	  
MOLREP	   (CCP4	   suite)	   [33,	   34],	   using	   the	   crystal	   structure	  of	  MICALFD	   as	   a	   search	  
model	  (PDB	  2BRA)	  [16].	  	  	  
	  
3.2.3.3	   Model	  Building	  and	  Refinement	  
The	   program	   COOT	   [35]	   was	   used	   for	   model	   building,	   and	   subsequent	  
rounds	   of	   refinement	  were	   performed	   in	   the	   program	   REFMAC	   (CCP4	   suite)	   [33,	  
34].	  The	  residues	  of	  the	  FD	  required	  little	  refinement	  since	  MICALFD	  was	  used	  as	  the	  
search	  model.	  A	  loop	  (amino	  acids	  147-­‐150)	  was	  missing	  from	  the	  MICALFD	  crystal	  
structure	  was	  since	  there	  was	  no	  density	  observed	  for	  it;	  this	  loop	  was	  modeled	  in	  
the	  current	  MICALFD-­‐CH	  crystal	  structure	  (Figure	  12).	  The	  residues	  of	  the	  CH	  domain	  
were	  manually	  built	  using	   the	  difference	  Fourier	  map.	   Initially,	  poly-­‐alanine	  alpha	  
helices	  were	  traced	  into	  well-­‐defined	  regions	  of	  the	  electron	  density.	  Then,	  the	  NMR	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model	  of	  human	  MICAL’s	  CH	  domain	  (PDB	  1WYL)	  was	  placed	  using	  the	  initially	  built	  
helices	   as	   a	   guide,	   followed	   by	   several	   rounds	   of	   refinement	   in	   REFMAC	   [33].	  
Refinement	  statistics	  are	  shown	  in	  Table	  3.1.	  
	   The	  structure	  from	  crystal	  1	  shows	  electron	  density	  for	  both	  the	  FD	  (residues	  
7-­‐484)	   and	   CH	   (residues	   511-­‐611)	   domains.	   However,	   there	   was	   no	   observable	  
electron	  density	   for	   residues	  485-­‐510	   (the	   linker	  between	   the	   two	  domains).	  This	  
introduced	   an	   uncertainty	   about	  which	   CH	   domain	   among	   three	   symmetry	  mates	  
belonged	  to	  the	  same	  molecule	  with	  given	  FD.	  Upon	  analysis	  of	  the	  asymmetric	  unit,	  
it	   appeared	   that	   the	   25-­‐residue	   linker	   could	   connect	   the	   FD	   to	   either	   of	   three	  
possible	  choices	  of	  a	  CH	  domain	  in	  the	  crystal	  asymmetric	  unit	  (Figure	  13).	  The	  first	  
step	   to	   resolve	   this	   ambiguity	  was	   to	  ensure	   that	  MICALFD-­‐CH	  had	  crystallized	  as	  a	  
single	   polypeptide	   chain,	   and	   that	   no	   cleavage	   had	   occurred	   at	   any	   stage	   after	  
purification	   and	   before	   crystallization.	   SDS-­‐PAGE	   analysis	   of	   re-­‐dissolved	   crystals	  
confirms	  that	  MICALFD-­‐CH	  crystallized	  as	  a	  single	  polypeptide	  chain	  (Figure	  14).	  
	  
3.2.3.4	   Native	  data	  collection	  from	  a	  2nd	  crystal	  (Crystal	  2)	  
	   X-­‐ray	  diffraction	  data	   from	  a	   second	   crystal	  was	   essential	   for	   resolving	   the	  
ambiguity	  in	  the	  FD	  and	  CH	  domain	  connectivity.	  Data	  was	  collected	  as	  described	  for	  
crystal	  1,	  with	   the	  only	  difference	  being	   that	   the	  MICALFD-­‐CH	  model	   from	  crystal	  1	  
was	  used	  as	  the	  molecular	  replacement	  search	  model	  for	  phase	  determination.	  The	  
model	  was	  built	  and	  refined	  in	  the	  same	  way	  as	  for	  crystal	  1.	  Even	  in	  this	  crystal,	  no	  
electron	  density	  was	  observed	  for	  the	  linker	  between	  the	  two	  domains.	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3.2.3.5	   Comparison	  of	  crystal	  1	  and	  crystal	  2	  unit	  cells	  
MICALFD-­‐CH	  crystallized	  in	  two	  different	  crystal	  forms	  sharing	  the	  same	  space	  
group	  with	  slightly	  different	  cell	  dimensions.	   In	  both	  crystal	   forms,	   the	  unit	   cell	   is	  
made	  by	  three	  layers	  stacking	  in	  the	  direction	  of	  the	  cell	  long	  axis,	  with	  two	  layers	  
formed	  exclusively	  by	  FD	  domains	   that	   sandwiches	  a	   layer	  of	  CH	  domains	   (Figure	  
15).	  The	  layer	  of	  FD	  domains	  makes	  the	  major	  crystal	  contacts	  across	  unit	  cells	  and	  
minor	  ones	  across	  the	  CH	  layer.	  Each	  FD	  in	  the	  asymmetric	  unit	  interacts	  with	  three	  
(four	  in	  crystal	  form	  2)	  CH	  domains	  (option	  1,	  2,	  3).	  
Examination	  of	  the	  asymmetric	  unit	  in	  crystal	  1	  and	  2	  shows	  that	  one	  FD	  can	  
connect	   to	   one	   of	   three	   possible	   CH	   domains.	   Superposition	   of	   the	   FD	   and	   its	  
respective	   CH	   domain	   connectivity	   options	   from	   crystal	   1	   onto	   that	   of	   crystal	   2,	  
followed	  by	   analysis	   of	  RMSD	  between	   the	  CH	  domain	  options	   from	  both	   crystals	  
clarified	   the	  connectivity	   (Figure	  13).	  The	  RMSD	  (Root	  Mean	  Square	  Deviation)	  of	  
option	  1	  and	  2	  from	  both	  crystals	  is	  3.7	  Å	  and	  3.8	  Å,	  respectively,	  while	  the	  RMSD	  for	  
option	  3	   is	  significantly	   lower	  at	  1.6	  Å.	  This	  suggests	   that	  option	  3	  shows	  the	  true	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Table	  1.	  MICALFD-­‐CH	  data	  colection	  and	  refinement	  statistics.	  
Data	  set	   Native	  #1	   Native	  #2	  
Data	  colection	   	   	  
Space	  Group	   P21	   P21	  
Cel	  dimensions	  (a,	  b,	  c)	   64.5,	  49.9,	  94.7	   70.2,	  50.2,	  97.0	  
Cel	  angles	  (α,	  β,	  γ),	  °	   90,	  107.9,	  90	   90,	  101.2,	  90	  
Resolution,	  Å	  (Last	  shel)	   90-­‐2.9	  	   95-­‐2.9	  
Total	  reflections	  (unique)	   45672	  (11353)	  	   52018	  (14602)	  
Completeness,	  %	  (Last	  shel)	   83.1	  (20.7)	  	   96.2	  (65.1)	  
I/σ	  (Last	  shel)	   9.3	  (1.4)	   6.6	  (1.1)	  
Rsym	  (Last	  shel)	   0.12	  (0.36)	   0.18	  (0.64)	  
Refinement	   	   	  
Rcrystal/Rfree	   0.27/0.30	   0.23/0.30	  
Stereochemistry	   	   	  
rms	  bond	  length,	  Å	   0.004	   0.006	  
rms	  angles,	  °	   0.8	   1.2	  
Temp	  factors,	  Å2	   	   	  
B-­‐factor	  protein	   19.4	   29.6	  
B-­‐factor	  FAD	   13.7	   15.9	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3.2.3.6	   SAXS	  analysis	  of	  MICALFD-­‐CH	  
	   To	   obtain	   further	   insight	   into	   the	   behavior	   of	   MICALFD-­‐CH	   in	   solution	   and	  
compare	  it	  with	  the	  model	  from	  the	  crystals,	  we	  performed	  SAXS	  (Small-­‐angle	  x-­‐ray	  
scattering)	   analysis	   on	  MICALFD-­‐CH.	   The	   overall	   SAXS	   parameters	   are	   presented	   in	  
Table	   3.2.	   At	   concentrations	   greater	   than	   3	   mg/ml	   MICALFD-­‐CH	   is	   in	   equilibrium	  
between	   a	  monomer	   and	   a	   dimer	   (option	   3),	   as	   evident	   by	   fitting	   the	   theoretical	  
scattering	   curves	   of	   an	   ensemble	   of	  monomer	   (~90	  %)	   and	   dimer	   (10	  %)	   to	   the	  
experimental	   data	   compared	  with	  monomer	   alone	   (Figure	   16)	   [36].	   Furthermore,	  
CH	  domain	  connectivity	  option	  1	  and	  option	  2	  fit	  the	  experimental	  data	  better	  than	  
option	  3.	  Option	  3	  has	  a	  lower	  estimated	  Rg	  of	  ~24	  Å	  than	  option	  1	  and	  2	  with	  an	  
estimated	  Rg	  of	  ~29	  Å,	  with	  the	  latter	  options	  matching	  the	  Rg	  calculated	  from	  the	  
experimental	  SAXS	  scattering	  curves.	  This	  suggests	  that	  the	  disordered	  linker	  allows	  
for	  some	  flexibility	  of	  the	  CH	  relative	  to	  the	  FD.	  
Table	  2.	  SAXS	  parameters	  of	  MICALFD-­‐CH.	  
Concentration	  (mg/ml)	   I(0)	   Rg	  (Å)	   Vp	  (Å3)	  
1	   27.5	   28.7	  
	  
102,000	  
2	   56.4	   29.3	   114,000	  
3	   90.6	   30.0	   122,000	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3.2.4	   Structure	  of	  MICALFD-­‐CH	  
	   The	   structure	   of	   MICALFD-­‐CH	   contains	   the	   FD	   and	   CH	   domains	   of	   mouse	  
MICAL-­‐1	  in	  the	  same	  polypeptide	  chain.	  MICALFD-­‐CH	  crystals	  contain	  one	  molecule	  in	  
the	  asymmetric	  unit	  (Figure	  17).	  	  
	  
The	  linker	  connecting	  the	  FD	  and	  CH	  domains	  
The	  FD	  and	  CH	  domains	  are	  connected	  by	  a	  25-­‐residue	  linker,	  which	  has	  no	  
observable	   electron	   density.	   This	   disordered	   linker	   (amino	   acids	   485-­‐510)	   is	   not	  
very	  well	  conserved	  amongst	  different	  MICALs.	  Based	  on	  its	  sequence,	  it	  is	  predicted	  
to	   be	   intrinsically	   unstructured	   by	   secondary	   structure	   prediction	   algorithms,	   for	  
example	  PSIPRED	  server	  (Expasy).	  
	  
Chromatographic	  behavior	  
Size	  exclusion	  chromatography,	  using	  a	  solution	  containing	  7	  mg/ml	  (~100	  
µM)	   of	   MICALFD-­‐CH,	   shows	   that	   MICALFD-­‐CH	   is	   monodisperse	   and	   behaves	   as	   a	  
monomer	   (Figure	   18),	   with	   an	   estimated	   molecular	   weight	   of	   ~63	   kDa,	   in	   good	  
agreement	  with	  the	  expected	  molecular	  weight	  of	  68	  kDa.	  
	  
Sequence	  conservation	  
	   From	   the	  N-­‐terminal	   FD	   (amino	   acids	   1-­‐484)	   to	   the	   end	   of	   the	   CH	  domain	  
(amino	  acids	  511-­‐611),	  MICAL-­‐1	  is	  highly	  conserved	  (Figure	  19)	  from	  Drosophila	  to	  
humans.	  	  With	  regards	  to	  humans,	  MICALFD-­‐CH	  from	  mouse	  used	  in	  this	  work	  is	  91%	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identical	   and	   93%	   similar	   to	   the	   MICALFD-­‐CH	   region	   of	   MICAL-­‐1	   in	   humans.	  
Therefore,	  it	  is	  very	  likely	  that	  the	  structure	  of	  a	  MICALFD-­‐CH	  construct	  from	  humans	  
is	  similar	  to	  that	  from	  mouse.	  
	  
Analysis	  of	  the	  interface	  contact	  between	  the	  FD	  and	  CH	  domains	  
	   Residues	   involved	   in	  contacts	  between	  the	  FD	  and	  CH	  domains	   include	  Met	  
232,	  Lys	  235,	  Ile	  264,	  Met	  369,	  Leu	  402,	  Arg	  408,	  Gln	  441,	  Leu	  442,	  Ser	  444,	  Gln	  445,	  
Ser	   447,	   Glu	   449,	   and	   Asn	   450	   from	   the	   FD.	   The	   aforementioned	   residues	   make	  
contacts	  with	   residues	  Leu	  553,	   Leu	  565,	  Thr	  569,	  Arg	  573,	  Val	   574,	  Glu	  576,	  His	  
577,	  Glu	  578,	  Gly	  580,	  Thr	  582,	  Pro	  583,	  Val	  584,	  Ser	  586,	  Gln	  588,	  and	  Ala	  609	  of	  
the	  CH	  domain	   (Figure	  20).	  A	  salt	  bridge	   is	   formed	  between	  Arg	  408	  and	  Glu	  576	  
side	   chains,	   and	   both	   these	   residues	   are	   conserved	   from	  Drosophila	   to	   human.	   A	  
hydrophobic	   contact	   between	   Ile	   264	   and	   Ala	   609	   is	   also	   present.	   The	   amide	  
nitrogen	  of	  Lys	  235	  makes	  a	  polar	  contact	  with	  the	  side	  chain	  of	  Glu	  578,	  as	  does	  the	  
side	  chain	  of	  Ser	  447	  and	  the	  carbonyl	  carbon	  of	  Pro	  583.	  
	   The	   interface	  has	  a	  solvent	  buried	  surface	  area	  of	  ~900	  Å3,	  and	  having	  this	  
large	  of	  a	  buried	  surface	  area	  is	  highly	  unlikely	  to	  be	  due	  to	  crystal	  contacts,	  further	  
supporting	   our	   current	   interpretation	   of	   option	   3	   being	   the	   CH	   belonging	   to	   the	  
asymmetric	  unit.	  
To	  test	  whether	  it	   is	   feasible	  to	  connect	  the	  FD	  and	  CH	  domains	  via	  the	  25-­‐
amino	  acid	  linker,	  the	  linker	  was	  modeled	  using	  MODELLER	  [37].	   It	   is	  possible	  for	  
the	   linker	   to	   connect	   the	   two	   domains,	   however,	   it	   is	   in	   a	   very	   extended	  
conformation.	   This	   raises	   the	   possibility	   that	   the	   connectivity	   observed	   in	   the	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crystal	  is	  a	  result	  of	  domain	  swapping;	  where	  the	  CH	  domain	  (option	  3)	  belongs	  to	  a	  
neighboring	   FD.	   Based	   on	   SAXS	   analysis,	   MICALFD-­‐CH	   is	   in	   equilibrium	   between	  
monomer	  and	  dimer	  at	  high	  concentrations	  (e.g.	   in	  a	  crystal).	  One	  important	  point	  
to	  note	  is	  that	  signaling	  proteins	  are	  typically	  found	  between	  10	  nM	  and	  1	  µM	  inside	  
the	  cytosol	  of	  a	  cell,	  nowhere	  near	  the	  concentration	  observed	  for	  oligomerization	  of	  
MICALFD-­‐CH.	  
	  
3.2.4.1	   Structure	  of	  the	  FD	  
	   The	  FD	  is	  a	  monooxygenase	  domain	  that	  consists	  of	  a	  mix	  of	  α-­‐helices	  and	  β-­‐
sheets.	   Both	   parallel	   and	   anti-­‐parallel	   β-­‐sheets	   can	   be	   found.	   Another	   structural	  
feature	  present	   in	   the	  FD	   is	  a	  Rossman	  β-­‐α-­‐β	   fold	  that	  contains	  a	  GXGXXG	  motif,	  a	  
sequence	   common	   in	   oxidoreductase	   enzymes	   dependent	   on	   NADPH	   and	   FAD	  
cofactors.	   The	   FAD	   cofactor	   in	   the	   active	   site	   that	   is	   necessary	   for	   the	   enzymatic	  
activity	  of	  MICAL	  [16]	  is	  oxidized,	  and	  is	  solvent-­‐accessible	  through	  a	  large	  opening	  
in	  the	  active	  site.	  It	  is	  highly	  similar	  to	  the	  structures	  of	  the	  isolated	  FD	  (PDB	  2BRA,	  
2BRY),	  with	  an	  rms	  deviation	  of	  0.5	  Å	  (Figure	  21)	  [16,	  20].	  
	  
3.2.4.2	   Structure	  of	  the	  CH	  domain	  
Structural	  description	  of	  the	  CH	  domain	  
The	   CH	   domain	   of	   MICALFD-­‐CH	   shares	   the	   same	   architecture	   as	   other	   CH	  
domains	   of	   the	   same	   type	   found	   in	   actin-­‐binding	   proteins:	   three	   parallel	   tightly	  
packed	   α-­‐helices,	   with	   a	   fourth	   α-­‐helix	   perpendicular	   to	   the	   other	   three.	   Key	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hydrophobic	   residues	   in	   these	   helices	   that	   are	   important	   for	   helix	   packing	   and	  
binding	   F-­‐actin	   are	   also	   conserved	   (Figure	   22).	   Structurally,	   the	   CH	   domain	   of	  
MICALFD-­‐CH	   construct	   is	   a	   type-­‐2	   CH,	   highly	   similar	   to	   the	   human	   MICAL-­‐1	   CH	  
domain	   (PDB	   1WYL),	   observed	   in	   the	   structure	   determined	   by	   NMR	   [21];	   the	  
structures	  align	  with	  a	  deviation	  of	  0.8	  Å	  rms	  (Figure	  23).	  
	  
Similarity	  to	  CH	  domains	  in	  actin-­‐binding	  proteins	  
The	  CH	  domain	  of	  MICALFD-­‐CH	  shows	  conserved	  structural	   features	  found	  in	  
the	   type-­‐2	   CH	   domains	   of	   actin-­‐binding	   proteins,	   such	   as	   conserved	   residues	   of	  
actin-­‐binding	   found	   in	   the	  helix	  perpendicular	   to	   the	  other	   three,	  and	  a	  conserved	  
PIP2	  binding	  site	  (Figure	  22,	  23)	  [18].	  
	  
3.2.5	   Structure-­‐function	  implications	   	  
What	  is	  immediately	  evident	  upon	  inspection	  of	  the	  structure	  is	  that	  the	  CH	  
domain	   in	  MICALFD-­‐CH	   is	  not	   located	  close	  to	   the	   large	  opening	  of	   the	  active	  site	  of	  
the	  FD.	  Thus,	  the	  CH	  domain	  does	  not	  interfere	  with	  accessibility	  to	  the	  active	  site	  of	  
the	  FD.	  This	  is	  consistent	  with	  kinetics	  data	  (Chapter	  2)	  that	  show	  that	  MICALFD	  and	  
MICALFD-­‐CH	  catalyze	  the	  oxidation	  of	  NADPH	  by	  O2	  with	  similar	  kinetics.	  	  
Furthermore,	  the	  presence	  of	  the	  CH	  domain	  does	  not	  significantly	  alter	  the	  
conformation	  of	  the	  active	  site	   in	  the	  FD.	  The	  FD	  in	  MICALFD-­‐CH	  aligns	  with	  a	  0.5	  Å	  
rms	  deviation	  (422	  residues	  aligned)	  to	  the	  MICALFD	  crystal	  structures	  (PDB	  2BRA,	  
2BRY).	  This	  is	  consistent	  with	  the	  modular	  nature	  of	  CH	  domains	  and	  the	  fact	  that	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the	  CH	  domain	  in	  MICALFD-­‐CH	  shares	  the	  same	  fold	  and	  architecture	  as	  the	  isolated	  
CH	  domain	  from	  human	  MICAL	  (PDB	  1WYL).	  	  
The	  CH	  domain	  of	  MICAL	   is	   close	   to	  where	  O2	   is	  predicted	   to	   enter	   the	  FD	  
active	   site	  near	   a	   small	   channel	   that	   opens	  upon	   reduction	  of	   the	  FAD	  by	  NADPH	  
[13,	  16,	  20].	  The	  conserved	  residues	  that	  form	  the	  actin-­‐binding	  segment,	  based	  on	  
sequence	   alignment	   and	   studies	   on	   CH	   domains	   in	   actin-­‐binding	   proteins,	   are	  
surface	  exposed	  and,	  relative	  to	  the	  FD,	  oriented	  in	  such	  a	  way	  that	  could	  bind	  actin	  
filaments	   and	   optimize	   the	   interaction	   between	   actin’s	   Met	   44	   (residue	   that	   is	  
oxidized	  in	  actin)	  and	  the	  FAD	  cofactor	  of	  MICAL.	  This	  optimization	  of	  the	  binding	  to	  
F-­‐actin	   may	   explain	   the	   kinetic	   data	   that	   shows	   an	   observed	   increase	   in	   redox	  
activity	  of	  MICALFD-­‐CH	  in	  the	  presence	  of	  F-­‐actin	  compared	  with	  MICALFD.	  In	  addition	  
to	  MICALFD-­‐CH	  being	   able	   to	  oligomerize	   at	   increasing	   concentrations,	   the	   fact	   that	  
the	  linker	  between	  the	  FD	  and	  CH	  domains	  is	  disordered	  and	  does	  not	  adopt	  a	  single	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3.3	   	   Conclusions	  and	  Discussion	  
The	  importance	  of	  the	  CH	  domain	  of	  MICAL	  has	  been	  highlighted	  by	  the	  fact	  
that	  it	  is	  highly	  conserved	  across	  all	  organisms	  possessing	  MICAL	  proteins	  [13],	  and	  
by	   experiments	   in	   Drosophila	   showing	   that	   axon	   guidance	   and	   MICAL-­‐mediated	  
actin	   modification	   requires	   the	   presence	   of	   the	   CH	   domain	   in	   vivo	   [5-­‐7].	  
Furthermore,	   even	   though	   it	   was	   previously	   known	   that	   CH	   domains	   are	   usually	  
involved	   in	  actin-­‐binding,	   the	  way	   in	  which	  this	  occurs	   for	  MICAL	  was	  not	  known.	  
The	  structure	  of	  MICALFD-­‐CH	  presented	  in	  this	  thesis	  work	  provides	  valuable	  insight	  
into	  the	  function	  of	  the	  CH	  domain.	  
	   The	  structure	  is	   in	  agreement	  with	  kinetics	  data	  (Chapter	  2)	  that	  show	  that	  
MICALFD	   and	   MICALFD-­‐CH	   catalyze	   the	   oxidation	   of	   NADPH	   by	   O2	   with	   similar	  
kinetics.	  This	  also	  supports	  a	  model	  of	  NADPH	  binding	  to	   the	   large	  opening	  of	   the	  
active	  site	  in	  the	  FD,	  based	  on	  observed	  electron	  density	  for	  Cl-­‐	   ion	  in	  the	  MICALFD	  
crystal	   structure	   (PDB	   2BRA)	   [16].	   In	   this	   model,	   the	   phosphate	   of	   NADPH	   is	  
modeled	  occupying	  the	  position	  where	  the	  Cl-­‐	  ion	  was	  observed	  (Figure	  24).	  
	   In	  the	  actin-­‐binding	  domains	  of	  proteins	  that	  cross-­‐link	  actin	  filaments	  (e.g.	  
α-­‐actinin,	   spectrin,	   dystrophin),	   the	   two	   tandem	   CH	   domains	   (type-­‐1	   and	   type-­‐2)	  
bind	  F-­‐actin	  with	  high	  affinity,	  and	  while	  CH	  type-­‐1	  can	  bind	  F-­‐actin	  alone,	  CH	  type-­‐
2	   alone	   cannot	   bind	   F-­‐actin	   [18].	   Furthermore,	   the	   structural	   data	   on	   the	   CH	  
domains	   of	   these	   actin-­‐binding	   proteins	   suggests	   that	   even	   though	   they	   are	   very	  
similar	  structurally,	   they	  do	  not	  bind	  F-­‐actin	   in	  a	  similar	  manner	   [38,	  39].	  The	  CH	  
domain	   of	   MICAL	   (type-­‐2)	   may	   be	   functioning	   in	   a	   similar	   way,	   where	   the	   FD	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functions	   as	   a	   type-­‐1	   CH	   domain	   in	   that	   it	   can	   bind	   F-­‐actin	   alone	   [6],	   and	   the	  
presence	  of	   the	  CH	  domain	  may	   increase	   the	  binding	  of	   the	  FD	   to	  F-­‐actin.	  Actinin,	  
utrophin,	   and	   dystrophin	   bind	   F-­‐actin	   in	   an	   open	   conformation	  whereas	   the	   free	  
proteins	  exist	  in	  a	  closed	  conformation.	  The	  ability	  of	  the	  two	  tandem	  CH	  domains	  to	  
undergo	   some	   conformational	   change	  with	   respect	   to	   each	   other	   upon	   binding	   F-­‐
actin	   is	   important,	  as	  mutations	  in	  the	  interface	  between	  the	  two	  tandem	  domains	  
that	  affects	  this	  result	  in	  disease	  phenotypes	  brought	  about	  by	  disregulation	  of	  the	  
F-­‐actin	  binding	  activity	  [39].	  Similarly,	  the	  disorder	  of	  the	  loop	  between	  the	  FD	  and	  
CH	   domains	   of	   MICAL	   may	   allow	   the	   two	   domains	   to	   accommodate	   for	   optimal	  
binding	  to	  F-­‐actin.	  
With	  kinetics	  and	  structural	   inferences	  taken	  together,	  we	  propose	  a	  model	  
of	  how	  the	  CH	  modulates	  the	  activity	  of	  MICAL	  in	  the	  presence	  of	  F-­‐actin	  (Figure	  25,	  
detailed	  explanation	   in	  Chapter	  4).	   In	   this	  model,	  NADPH	  can	  enter	   the	  active	  site	  
from	   the	   large	   opening	   (as	   modeled	   in	   Figure	   24),	   and	   Met	   44	   of	   actin	   can	   be	  
accommodated	  through	  the	  small	  channel	   that	  opens	  up	  on	  the	  other	  side.	  Kinetic	  
data	  of	  MICALFD-­‐CH	  redox	  activity	  as	  a	  function	  of	  increasing	  F-­‐actin	  suggests	  that	  the	  
KM	  of	  NADPH	  binding	  does	  not	  change;	  only	  the	  kcat	  is	  increased,	  further	  supporting	  
this	  model.	  Met	  44	  of	  actin,	   the	  residue	  modified	  by	  MICAL,	   is	   contained	   in	   the	  D-­‐
loop	  of	  actin	  (residues	  39-­‐52).	  It	  was	  shown	  experimentally	  that	  the	  D-­‐loop	  of	  actin	  
is	   flexible	   and	   that	   in	   solution	   it	   can	   adopt	   multiple	   conformations	   [40].	   It	   is	  
disordered	   in	   most	   crystal	   structures	   of	   actin,	   and	   does	   not	   adopt	   the	   same	  
conformation	  in	  the	  structures	  in	  which	  it	  was	  observed.	  It	  is	  located	  at	  the	  pointed	  
end	   of	   the	   actin	   monomer,	   and	   makes	   extensive	   electrostatic	   and	   hydrophobic	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contacts	   with	   the	   adjacent	   monomer	   in	   the	   F-­‐actin	   filament	   [41].	   Thus,	   the	  
conformation	  and	  integrity	  of	  the	  D-­‐loop	  is	  important	  for	  filament	  stability	  [42].	  The	  
flexibility	  of	   the	  D-­‐loop	  may	  also	  be	   important	   for	  allowing	   it	   to	  bind	  optimally	   to	  
MICAL	  for	  oxidation	  by	  the	  reduced	  FAD.	  	  
	  
	  






Figure	  9.	  Purification	  of	  MICALFD-­‐CH.	  
(A)	   Purification	   of	   MICALFD-­‐CH	   with	   nickel	   affinity	   chromatography	   and	   cation	  
exchange	  chromatography.	  Left:	  chromatogram	  from	  a	  HistrapTM	  HP	  column.	  Right:	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A:	  after	  TEV	  cleavage,	  
before	  cation	  exchange	  
	  
H:	  fractions	  16-­‐24	  from	  
nickel	  affinity	  
chromatography	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Figure	  16.	  Comparison	  of	  theoretical	  and	  experimental	  scattering	  from	  SAXS.	  
Experimental	   data	   is	   indicated	   in	   black	   filled	   circles,	   and	   theoretical	   scattering	   fit	  
through	  the	  experimental	  data	  is	  indicated	  by	  solid	  colored	  line.	  Op1:	  option	  1;	  op2:	  
option	  2;	  op3;	  option	  3;	  dimer:	  domain-­‐swapped	  dimer	  of	  option	  3.	  (A)	  Fit	   for	  low	  
concentration	   (merged	   dataset	   of	   MICALFD-­‐CH	   1,	   2,	   3	   mg/ml).	   Table	   shows	   the	  
theoretical	   Rg	   for	   each	   option.	   (B)	   Multiple	   ensemble	   search	   (MES)	   fit	   compared	  






PDB	  file	  	   χ	  	   Rg	  
op1	   0.66	   28.17	  
op2	   0.71	   29.01	  
op3	   1.17	   24.52	  
dimer	   1.27	   35.62	  
MES	  Fit	  	   χ	  =	  2.033499	  
File	  name	  	   Weight	  	  
dimer	  	   0.17148880	  	  
op2	  	   0.82820862	  	  
Single	  PDB	  Best	  Fit	  	  χ	  =	  2.38606	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Figure	  19.	  Sequence	  alignment	  of	  MICAL-­‐1	  homologues.	  	  
MICAL	  sequences	   from	  the	   indicated	  organisms	  were	  aligned	  from	  the	  N-­‐terminus	  
to	  the	  end	  of	  the	  CH	  domain	  (aa	  1-­‐615).	  Alignment	  was	  performed	  using	  ClustalW.	  
Figure	  prepared	  with	  ESPript.	  Interface	  residues	  underlined	  with	  an	  arrowheads.	  
	  
	   59	  
	  
Figure	  19.	  Sequence	  alignment	  of	  MICAL-­‐1	  homologues	  (Cont.).	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Figure	  19.	  Sequence	  alignment	  of	  MICAL-­‐1	  homologues	  (Cont.).	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Figure	  20.	  Overview	  of	  the	  interface	  between	  the	  FD	  and	  CH	  domains.	  
FD	  is	  shown	  in	  yellow,	  and	  the	  CH	  domain	  is	  shown	  in	  cyan.	  Interface	  residues	  are	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4.	  Model	  of	  MICALFD-­‐CH	  Bound	  to	  Actin	  
	  
The	  crystal	  structure	  of	  MICALFD-­‐CH	  (described	  in	  Chapter	  3)	  reveals	  that	  the	  
CH	  domain	  is	  connected	  to	  the	  FD	  with	  a	  disordered	  linker.	  This	  may	  be	  important	  
for	  better	  accommodating	  the	  binding	  of	  the	  FD	  to	  actin,	  so	  that	  it	  can	  oxidize	  actin	  
residue	   M44.	   Since	   it	   is	   technically	   challenging	   to	   obtain	   crystals	   of	   F-­‐actin,	   or	  
MICALFD-­‐CH	   bound	   to	   F-­‐actin,	   this	   chapter	   describes	   the	   use	   of	   a	   computational	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4.1	   	   Introduction	  
MICAL	   modifies	   F-­‐actin	   by	   oxidation	   of	   a	   methionine	   (residue	   Met44)	   to	  
methionine	   sulfoxide,	   and	   this	   is	   thought	   to	   destabilize	   the	   filament	   and	   lead	   to	  
depolymerization	  [7].	  It	  is	  unknown	  whether	  this	  oxidation	  is	  direct,	  where	  during	  
the	   reaction	  Met44	   is	   close	  enough	   to	   the	  C4a	  atom	  of	   the	   reduced	  FAD	  (the	  C4a-­‐
hydroperoxyflavin	   FAD	   intermediate)	   isoalloxazine	   ring	   (FAD-­‐C4a),	   for	   direct	  
transfer	  of	  the	  oxygen	  atom,	  or	  whether	  the	  oxidation	  is	  indirect,	  where	  the	  NADPH	  
oxidase	  activity	   leads	  to	  a	  high	   local	  concentration	  of	  H2O2,	  and	  the	  H2O2	  transfers	  
an	  oxygen	  to	  the	  methionine	  [13,	  14].	  An	  atomic-­‐resolution	  structure	  of	  MICALFD-­‐CH	  
bound	  to	  F-­‐actin	  would	  significantly	  aid	   in	  resolving	  this.	  F-­‐actin	   is	  a	  polymer	  that	  
can	  be	  very	  large;	  a	  solution	  of	  which	  will	  contain	  many	  polymers	  of	  different	  sizes.	  
In	  addition	  to	  purity,	  proteins	  should	  be	  soluble	  and	  conformationally	  homogenous	  
to	   yield	   crystals.	   F-­‐actin	   has	   thus	   proven	   difficult	   to	   crystallize,	   and	   the	   highest	  
resolution	  model	  obtained	  thus	  far	   is	  by	  x-­‐ray	  fiber	  diffraction	  of	  F-­‐actin	  polymers	  
oriented	  in	  a	  magnetic	  field	  (PDB	  2ZWH)	  [43].	  Thus,	  it	  is	  technically	  challenging	  to	  
obtain	  an	  atomic-­‐resolution	  structure	  of	  a	  complex	  of	  MICALFD-­‐CH	  and	  F-­‐actin.	  	  
The	  residue	  of	  actin	  that	  MICAL	  oxidizes,	  Met44,	  is	  well	  below	  the	  surface	  of	  
F-­‐actin.	   For	   a	   direct	   oxidation	   reaction	   to	   be	   possible,	   a	   conformation	   should	   be	  
found	  in	  which	  the	  D-­‐loop	  can	  reach	  to	  the	  active	  site	  of	  the	  FD	  in	  such	  a	  way	  that	  
the	   Sulfur	   atom	   of	   the	   methionine	   is	   within	   ~3	   Å	   of	   FAD-­‐C4a.	   Direct	   oxidation	  
cannot	   be	   possible	   if	   the	   Sulfur	   atom	   is	   too	   far	   away	   from	   FAD-­‐C4a.	   This	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conformation	  should	  be	  accessible	   from	  observed	  structures	  without	  breaking	  any	  
covalent	  bonds	  or	  affecting	  the	  structural	  integrity	  of	  either	  actin	  or	  MICAL.	  	  
As	   described	   in	   the	   section	   3.3,	   the	   actin	   D-­‐loop	   is	   flexible	   and	   can	   adopt	  
multiple	  conformations	  in	  solution,	  depending	  on	  the	  nucleotide	  state	  or	  the	  protein	  
that	   it	   is	   bound	   to.	   Furthermore,	   in	   the	   crystal	   structures	  where	   it	   is	   visible,	   it	   is	  
observed	   to	   adopt	   different	   conformations.	   The	   D-­‐loop	   makes	   extensive	  
electrostatic	   and	   hydrophobic	   contacts	  with	   the	   adjacent	  monomer	   in	   the	   F-­‐actin	  
filament	   [10,	   41,	   43],	   and	   chemical	   modifications	   in	   the	   D-­‐loop	   dramatically	  
decrease	   the	   thermal	   stability	   of	   F-­‐actin	   [44].	   Thus,	   even	   though	   the	   D-­‐loop	   is	  
flexible	  and	  able	  to	  adopt	  multiple	  conformations	  in	  monomeric	  actin	  as	  well	  as	  in	  
the	  actin	  filament,	  its	  conformation	  and	  integrity	  is	  important	  for	  filament	  stability	  
[41].	  
In	  this	  thesis,	  a	  computational	  approach	  was	  used	  to	  propose	  a	  model	  of	  this	  
complex,	  and	  test	  whether	  direct	  oxidation	  of	  actin	  by	  MICAL	  is	  possible.	  With	  the	  
crystal	   structure	   of	   MICALFD-­‐CH	   and	   a	   dimer	   from	   the	   highest	   resolution	   F-­‐actin	  
model	   (PDB	   2ZWH),	   molecular	   dynamics	   simulations	   were	   performed.	   The	  
simulations	   involved	   gentle	   steering	   of	   actin’s	   M44	   towards	   FAD-­‐C4a,	   to	   assess	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4.2	   	   Model	  Building	  
A	  model	  of	  the	  complex	  of	  MICALFD-­‐CH	  and	  F-­‐actin	  was	  made	  using	  the	  crystal	  
structure	  of	  MICALFD-­‐CH	   reported	   in	   this	   study	  and	  a	  dimer	  of	  actin	   from	   the	  most	  
recent	  F-­‐actin	  model	  (PDB	  2ZWH),	  shown	  in	  Figure	  25.	  The	  conformation	  of	  the	  FAD	  
in	  the	  MICALFD-­‐CH	  structure	  was	  replaced	  by	  the	  one	  present	  in	  the	  crystal	  structure	  
of	   the	   FD	  with	   the	   reduced	   FAD	   (PDB	   2C4C).	   To	   obtain	   a	   starting	  model,	   the	   CH	  
domain	   of	   MICALFD-­‐CH	   was	   aligned	   to	   the	   CH	   domain	   of	   an	   electron	   microscopy	  
model	   of	   actinin	  bound	   to	  F-­‐actin	   (PDB	  3LUE),	   followed	  by	  manual	   adjustment	   of	  
MICALFD-­‐CH	  to	  orient	  the	  opening	  of	  the	  active	  site	  (opposite	  the	  site	  where	  NADPH	  
is	  predicted	  to	  bind,	  Figure	  24)	  in	  the	  FD	  towards	  the	  D-­‐loop	  of	  actin	  that	  contains	  
M44,	  whilst	  maintaining	   the	   contact	  between	   the	  CH	  domain	  and	  actin.	   For	  direct	  
oxidation	  to	  be	  possible,	  the	  D-­‐loop	  must	  adopt	  a	  conformation	  in	  which	  the	  sulfur	  
atom	  of	  M44	  is	  within	  ~3	  Å	  of	  FAD-­‐C4a	  in	  MICALs	  active	  site.	  	  
	  
4.2.1	   Molecular	  Dynamics	  Simulation	  
	   To	  assess	  whether	  a	  conformation	  of	  the	  D-­‐loop	  in	  which	  M44	  is	  close	  to	  the	  
FAD-­‐C4a	  is	  possible,	  molecular	  dynamics	  calculations	  were	  performed	  (see	  chapter	  
5	   for	   brief	   background	   on	  molecular	   dynamics).	   CHARMM	   version	   28b2	  with	   the	  
CHARMM	  28b2	  [45]	  force	  field	  was	  used	  in	  the	  computations	  with	  implicit	  solvent	  
and	  a	  distance	  dependent	  dielectric	  constant.	  For	  all	  calculations,	  the	  FAD	  cofactor	  
was	   harmonically	   constrained	   to	   either	   the	   oxidized	   “out”	   conformation	   or	   the	  
reduced	   “in”	   conformation	   with	   a	   force	   constant	   of	   1	   kcal/mol	   Å2.	   The	   original	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coordinates	  of	  this	  model	  were	  optimized	  by	  minimizing	  the	  energy	  for	  1000	  cycles	  
of	  steepest	  descent,	  followed	  by	  1000	  cycles	  of	  conjugate	  gradient,	  and	  finally	  1000	  
cycles	  of	  adopted-­‐basis	  Newton-­‐Raphson	  minimization.	  Leap	  frog	  Verlet	  molecular	  
dynamics	  simulations	  were	  performed	  at	  constant	  temperature	  of	  300	  K	  and	  run	  for	  
30,000	  fs,	  harmonically	  constraining	  M44	  to	  a	  chosen	  position	  with	  a	  force	  constant	  
of	  0.5	  kcal/mol	  Å2.	  In	  each	  successive	  simulation,	  M44	  was	  constrained	  to	  a	  position	  
closer	   to	   the	  FAD-­‐C4a	  atom,	  until	   the	  D-­‐loop	  achieved	  a	   conformation	  where	  M44	  
was	  within	  the	  3	  Å	  range	  required	  for	  oxidation	  to	  be	  possible.	  The	  average	  value	  of	  
the	  energy	  and	  its	  fluctuations	  during	  the	  last	  10,000	  fs	  were	  calculated	  with	  an	  in-­‐
house	   written	   program.	   Structural	   representations	   were	   prepared	   with	   the	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4.3	   	   Results	  
	  
4.3.1	   Model	   of	   the	   Arrangement	   for	   Direct	   Oxidation	  
of	  Actin	  by	  MICAL	  
	   Upon	   reduction	   by	   NADPH,	   the	   FAD	   cofactor	   of	   MICAL	   undergoes	   a	  
conformational	   change	   from	   the	   oxidized	   “out”	   conformation	   to	   the	   reduced	   “in”	  
conformation	   that	   renders	   it	   less	   accessible	   to	   solvent.	   The	   molecular	   dynamics	  
simulations	   reveal	   that	   it	   is	   possible	   to	   attain	   a	   D-­‐loop	   conformation	   of	   actin	   in	  
which	  M44	   is	   in	   close	  proximity	   to	   the	   reduced	  FAD-­‐C4a	   (hereafter	   referred	   to	  as	  
“D-­‐loop	   out”	   conformation),	   as	   shown	   in	   Figure	   26.	   The	   major	   conformational	  
change	  is	  in	  the	  D-­‐loop	  itself;	  no	  other	  structural	  changes	  in	  other	  parts	  of	  the	  actin	  
monomer	   are	   observed.	   The	   fact	   that	   this	   conformation	   can	   be	   reached	   in	   a	  
molecular	  dynamics	  simulation,	  using	  gentle	  steering	  and	  without	  the	  need	  to	  break	  
bonds	   or	   significantly	   alter	   the	   integrity	   of	   either	   structure,	   indicates	   that	   this	  
conformation	   can	   be	   populated	   with	   a	   high	   enough	   frequency	   to	   be	   kinetically	  
competent.	  	  
Given	   that	   the	   D-­‐loop	   itself	   undergoes	   a	   large	   conformational	   change	  
required	   to	  adopt	   the	  “D-­‐loop	  out”	  conformation	  (Figure	  26),	   the	  energetic	  cost	  of	  
adopting	  this	  conformation	  was	  estimated	  by	  a	  series	  of	  short	  molecular	  dynamics	  
simulations.	   The	   potential	   energy,	   averaged	   over	   the	   production	   phase	   of	   the	  
simulation,	  was	  compared	  between	  simulations	  for	  an	  actin	  monomer	  where	  the	  D-­‐
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loop	  is	  in	  the	  “D-­‐loop	  out”	  conformation	  (with	  FAD	  either	  oxidized	  or	  reduced)	  and	  
an	  actin	  monomer	  whose	  D-­‐loop	  is	  at	  the	  starting	  conformation	  found	  in	  the	  original	  
PDB	  by	  Oda	  et	  al.	  The	  energy	  of	  the	  “D-­‐loop	  out”	  conformation	  is	  within	  2%	  of	  the	  
original	  conformation	  (Table	  3).	  
	  
Table	  3.	  Average	  energies	  from	  molecular	  dynamics	  simulations.	  
	   Initial	   D-­‐loop	  out	  
Potential	   3604.90	   3548.62	  
Bond	   1004.31	   1009.02	  
Angle	   2560.50	   2552.89	  
Dihedral	   1930.89	   1918.92	  
Improper	   177.15	   178.00	  
Van	  der	  Waals	   -­‐1804.69	   -­‐1827.88	  
Electrostatic	   -­‐593.64	   -­‐609.05	  
Harmonic	   3.97	   2.42	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4.4	   	   Conclusions	  and	  Discussion	  
	   Although	   our	   model	   suggests	   that	   direct	   oxidation	   of	   actin	   by	   MICAL	   is	  
possible,	   it	   cannot	   be	   ruled	   out	   that	   actin	  Met44	   oxidation	   occurs	   by	   a	   high	   local	  
increase	  in	  H2O2	  concentration	  upon	  binding.	  F-­‐actin	  stimulates	  the	  NADPH	  oxidase	  
activity	  of	  MICAL,	  and	  it	  is	  known	  that	  reduced	  FAD	  can	  either	  combine	  with	  O2	  to	  
form	  a	  C4a	  hydroperoxidate	  that	  can	  release	  H2O2	  or	  directly	  oxidize	  its	  substrate.	  
This	  model	  does	  not	  rule	  out	  the	  possibility	  that	  Met44	  is	  the	  residue	  of	  actin	  that	  is	  
oxidized	  directly,	   and	  Met47	   can	   become	   oxidized	   indirectly	   by	   H2O2.	   Both	  Met44	  
and	  Met47	   are	   oxidized	   upon	   addition	   of	  MICAL	   and	  NADPH	   to	   F-­‐actin;	   however,	  
MICAL	   failed	   to	   depolymerize	   actin	   M44L	   mutants,	   but	   could	   still	   depolymerize	  
actin	  M47L	  mutants	  [7].	  Both	  these	  mutants	  were	  able	  to	  polymerize	  normally	  into	  
F-­‐actin	   and	   able	   to	   bind	   MICAL.	   Given	   the	   position	   of	   Met47	   in	   the	   “D-­‐loop	   out”	  
conformation,	   this	   hypothesis	   is	   indeed	   possible.	   Future	   work	   using	  mutagenesis	  









Figure	  25.	  Model	  for	  MICALFD-­‐CH	  complex	  with	  F-­‐actin.	  
(A)	  Overview	  of	  MICALFD-­‐CH	  interaction	  with	  F-­‐actin	  in	  the	  model	  used	  for	  molecular	  
dynamics	  simulations.	  FD	  is	  in	  yellow,	  CH	  in	  cyan,	  individual	  actin	  monomers	  from	  a	  
polymer	  of	  F-­‐actin	  (PDB	  2ZWH)	  are	  in	  magenta,	  pink,	  red,	  and	  green.	  Actin’s	  Met44	  













In	  this	  thesis,	  structural	  characterization	  of	  MICALFD-­‐CH	  fragment	  was	  used	  to	  
evaluate	  the	  effect	  of	  the	  presence	  of	  the	  CH	  domain	  on	  the	  FD.	  The	  most	  commonly	  
used	  method	   for	   high-­‐resolution	   structure	   determination	   of	  macromolecules	   is	   x-­‐
ray	   crystallography,	   and	   this	   was	   the	  method	   used	   to	   determine	   the	   structure	   of	  
MICALFD-­‐CH.	   Structure	   determination	   by	   x-­‐ray	   crystallography	   is	   no	   trivial	  
undertaking;	   there	  can	  be	  no	  structure	  without	  a	  protein	  crystal.	   In	   this	  chapter,	   I	  
will	  describe	  at	  a	  very	  basic	  level	  the	  theory	  behind	  x-­‐ray	  crystallography	  and	  its	  use	  
in	  structure	  determination.	  In	  the	  final	  section	  I	  will	  discuss,	  at	  a	  very	  basic	  level,	  the	  
theory	   behind	   computational	   molecular	   dynamics	   (MD)	   simulations.	   MD	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5.1	   	   X-­‐ray	  Crystallography	  
	   Before	  introducing	  the	  method	  of	  x-­‐ray	  crystallography,	  I	  will	  provide	  a	  brief	  
account	  of	  “x-­‐rays”	  and	  “crystals”,	  both	  of	  which	  are	  fundamental	   for	  ability	  to	  use	  
this	   method.	   X-­‐rays	   are	   a	   form	   of	   electromagnetic	   radiation	   of	   high	   energy,	   with	  
wavelengths	  of	  0.2	  –	  0.01	  nm.	  Upon	  interaction	  with	  macromolecules,	  the	  electrons	  
in	   the	   atoms	   of	   the	   macromolecule	   cause	   the	   x-­‐rays	   to	   scatter	   from	   the	   original	  
incident	   beam	   direction.	   This	   pattern	   of	   “diffracted”	   x-­‐rays	   can	   be	   detected	   and	  
measured	  to	  reconstruct	  the	   image	  of	   the	  scattering	  macromolecule	  [47]	  [48].	  The	  
diffraction	  pattern	  from	  a	  single	  macromolecule	  is	  too	  weak	  to	  detect,	  however.	  To	  
circumvent	   this	   problem,	   crystals	   of	   a	  macromolecule	   are	   required.	   Crystals	   are	   a	  
solid-­‐state	   form	  of	  matter	   containing	   a	   large	   number	   of	   the	   same	  macromolecule,	  
arranged	  in	  a	  periodic	  and	  ordered	  manner.	  
	   X-­‐ray	  crystallography	  involves	  passing	  an	  x-­‐ray	  beam	  through	  a	  crystal	  of	  a	  
macromolecule.	   Since	   a	   crystal	   contains	   many	   macromolecules,	   each	   of	   which	  
contains	   many	   atoms	   and	   their	   respective	   electrons,	   there	   are	   many	   scattered	  
waves	  of	   x-­‐rays.	  These	  waves	   either	   constructively	   or	  destructively	   interfere	  with	  
each	  other,	   and	   the	  measured	  diffraction	  pattern	   from	  a	  diffraction	  dataset	   shows	  
discrete	  points	  (with	  a	  given	  intensity)	  that	  are	  a	  result	  of	  constructive	  interference	  
of	  the	  aforementioned	  waves	  (shifted	  with	  respect	  to	  each	  other	  by	  a	  certain	  phase).	  
	   A	  Fourier	  transform	  of	  the	  diffraction	  data	  is	  used	  to	  reconstruct	  the	  electron	  
density	  of	  the	  scattering	  macromolecule.	  However,	  only	  the	  intensity	  of	  the	  discrete	  
points	  can	  be	  obtained	  experimentally	   from	  the	  diffraction	  data;	  phases	  cannot	  be	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obtained.	   This	   is	   the	   so-­‐called	   “phase	   problem”	   in	   x-­‐ray	   crystallography.	   This	   is	  
addressed	   experimentally	   by	   addition	   of	   heavy	   atoms	   to	   use	   isomorphous	  
replacement,	  or	  addition	  of	  anomalous	  scatterers	  to	  use	  anomalous	  diffraction.	  The	  
phase	  problem	  can	  also	  be	  addressed	  without	  the	  need	  for	  additional	  experiments;	  
if	   a	   model	   with	   greater	   than	   30%	   identity	   and	   similar	   structure	   to	   the	  
macromolecule	  from	  the	  crystal	  is	  available,	  the	  information	  from	  this	  search	  model	  
can	  be	  used.	   This	   approach	   is	   called	  molecular	   replacement,	   and	  was	   successfully	  
applied	  in	  this	  thesis	  work	  to	  obtain	  missing	  phases	  for	  structure	  determination.	  In	  
this	  section,	  I	  will	  introduce	  very	  briefly	  some	  background	  on	  x-­‐ray	  diffraction,	  the	  
method	  of	  molecular	   replacement	   for	   phase	   determination,	   and	   refinement	   of	   the	  
atomic	   models.	   For	   a	   more	   detailed	   discussion	   on	   the	   theory	   behind	   x-­‐ray	  
crystallography,	  I	  refer	  you	  to	  the	  textbook	  by	  Bernhard	  Rupp	  [49].	  	  	  	  
	  
5.1.1	   X-­‐ray	  diffraction	  theory	  
Diffraction	  from	  a	  crystal	  
The	   complex	   structure	   factor	  Fh,	   which	   describes	   the	   scattering	   in	   a	   given	  
direction	  h	  by	  the	  summation	  of	  the	  scattering	  contributions	  fj	  of	  j	  atoms	  at	  position	  
xj	  in	  the	  unit	  cell,	  can	  be	  expressed	  as:	  
€ 
Fh = f j ⋅ exp 2πihx j( )
j
atoms




	   79	  
Bragg’s	  Law	  
In	   order	   for	   reflections	   of	   the	   scattered	   x-­‐rays	   to	   appear	   during	   data	  
collection,	  they	  must	  be	  scattered	  at	  certain	  angles	  relative	  to	  the	  incident	  beam.	  If	  
the	   scattering	   angle	   is	   an	   integer	   multiple	   of	   the	   wavelength,	   the	   resulting	  
diffraction	  will	  be	  non-­‐zero:	  
€ 
nλ = 2dhkl sinθ 	   	   	   	   (5.2)	  
This	   is	   known	   as	   Bragg’s	   law,	   and	   is	   a	   consequence	   of	   the	   periodicity	   of	   the	  
macromolecules	  in	  the	  crystal.	  
	  
Reconstructing	  the	  electron	  density	  
Rewriting	  the	  structure	  factor	  equation	  (5.x)	  in	  terms	  of	  spatial	  distribution	  
over	  the	  entire	  volume	  V	  of	  the	  unit	  cell:	  
€ 






∫ 	  	   	   (5.3)	  
where	  
€ 
ρ(xyz)	   is	  the	  electron	  density	  at	  the	  coordinates	  xyz.	  Expressing	  
€ 
ρ(xyz)	  as	  a	  
function	  of	  
€ 
F(hkl) ,	  we	  obtain:	  
	  
€ 
ρ xyz( ) =1/V F(hkl)
l∫k∫h∫ exp −2πi hx + ky + lz( ) + iα hkl( )[ ]	   	   (5.4)	  
where	  
€ 
α(hkl) 	   is	   the	   phase	   of	   the	   reflection	  
€ 
(hkl) .	   From	   the	   experimental	   data	  







F(hkl) 2.	   The	   phases	   need	   to	   be	   determined	   by	   one	   of	   the	  
methods	  mentioned	  in	  the	  next	  section.	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5.1.2	   Phase	  Determination	  
In	  order	  to	  obtain	  the	  phases	  required	  for	  reconstructing	  the	  electron	  density	  
of	   the	  scattering	  macromolecule,	   the	  most	  common	  methods	  are:	  (1)	   isomorphous	  
replacement,	  (2)	  anomalous	  diffraction,	  and	  in	  the	  case	  where	  a	  structurally	  similar	  
model	   is	   available	   (3)	   molecular	   replacement.	   Since	   in	   this	   thesis	   work	   the	  
molecular	   replacement	   method	   was	   used,	   a	   very	   brief	   background	   is	   provided	  
below.	  
	  
5.1.2.1	   Molecular	  replacement	  
Since	   this	   method	   does	   not	   require	   any	   experimental	   setup,	   and	   with	   the	  
large	   number	   of	   structures	   currently	   available	   in	   the	   protein	   data	   bank	   (PDB),	  
molecular	  replacement	  is	  the	  most	  commonly	  used	  method	  to	  obtain	  missing	  phases	  
in	  structure	  determination.	  The	  condition	  is	  that	  there	  must	  be	  an	  existing	  structure	  
with	  greater	  than	  30%	  identity	  to	  use	  as	  a	  search	  model.	  
	   To	   determine	   the	   phases	   of	   an	   unknown	   structure,	   the	   search	  model	  with	  
known	   phases	   is	   relocated	   and	   structure	   factors	   are	   calculated.	   This	   is	   repeated	  
until	  the	  calculated	  structure	  factors	  of	  the	  search	  model	  are	  in	  agreement	  with	  the	  
observed	  structure	  factors	  of	  the	  unknown	  structure.	  Although	  this	  six-­‐dimensional	  
search	  problem	  is	  fine	  in	  theory,	  macromolecules	  contain	  many	  atoms	  (on	  the	  order	  
of	   10,000)	   and	   searching	   each	   of	   the	   six	   degrees	   of	   freedom	   is	   computationally	  
inefficient	  and	  expensive.	  A	  more	  efficient	  way	  to	  approach	  this	  problem	  is	  to	  use	  a	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three-­‐dimensional	   rotation	   search	   followed	   by	   a	   three-­‐dimensional	   translation	  
search.	  
	   In	   this	   way,	   the	   search	   begins	   with	   finding	   the	   proper	   orientation	   of	   the	  
known	  structure	   in	  the	  crystal	  using	  a	  rotation	  function.	  Once	  this	   is	  achieved,	   the	  
search	  for	  the	  correct	  position	  of	  the	  molecule	  in	  the	  unit	  cell	  is	  carried	  out	  using	  a	  
translation	  function.	  After	  each	  step	  of	  the	  rotation	  and	  translation	  search,	  structure	  
factors	   for	   the	   search	   model	   are	   calculated	   and	   evaluated	   against	   the	   structure	  
factors	  of	  the	  unknown	  structure,	  until	  an	  acceptable	  agreement(s)	  is	  found.	  
	   Molecular	  replacement	  can	  only	  be	  used	  if	  a	  structure	  of	  a	  highly	  homologous	  
model	  in	  a	  similar	  conformation	  is	  available.	  Success	  of	  this	  method	  also	  depends	  on	  
the	  quality	  of	  the	  diffraction	  data	  obtained	  from	  the	  data	  collection.	  
	  
5.1.3	   Refinement	  
	   Once	  the	  phases	  are	  obtained,	  the	  electron	  density	  can	  be	  reconstructed,	  and	  
model	  building	  ensues.	  To	  ensure	   that	   the	  model	  built	   is	   free	  of	  errors,	   the	  model	  
undergoes	   several	   rounds	   of	   refinement.	   The	   agreement	   between	   the	   built	  model	  









	   	   	   	   	   (5.5)	  
The	  R-­‐value	  measures	   the	  difference	  between	   the	  observed	  structure	   factors	   from	  
the	   diffraction	   data	   collected	   and	   the	   calculated	   structure	   factors	   from	   the	   built	  
model.	  Refinement	  is	  carried	  out	  until	  convergence	  is	  achieved.	  To	  ensure	  that	  the	  
	  
	   82	  
model	   does	   not	   contain	   any	   bias,	   the	   R-­‐value	   is	   calculated	   in	   the	   same	   way	   as	  
mentioned	  above,	  but	  with	  5-­‐10%	  of	  the	  observed	  reflections	  removed;	  this	  R-­‐value	  
is	  termed	  R-­‐free.	  In	  an	  unbiased	  refinement,	  the	  difference	  between	  the	  R-­‐value	  and	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5.2	   	   Molecular	  Dynamics	  Simulation	  
The	   atomic	   resolution	   structures	   of	   macromolecules	   determined	   by	   x-­‐ray	  
crystallography	  are	  extremely	  valuable	  in	  providing	  detailed	  structural	  insight	  into	  
their	  function	  that	  cannot	  be	  obtained	  from	  experimental	  work	  alone.	  	  However,	  the	  
structure	  represents	  a	  single	  conformation	  of	  a	  dynamic	  macromolecule.	  One	  of	  the	  
most	  widely	  used	  methods	  to	  obtain	  dynamic	  information	  about	  macromolecules	  is	  
Molecular	   Dynamics	   (MD)	   simulations.	   MD	   simulations	   are	   used	   to	   simulate	  
motions	   of	  macromolecules	   as	   a	   function	  of	   time	   in	   silico.	   Information	   concerning	  
structural	   and	   dynamic	   properties	   can	   be	   obtained	   from	   MD,	   such	   as	   molecular	  
geometries,	   local	   fluctuations,	   and	   nature	   of	   various	   types	   of	   motions.	   This	  
technique	  was	  used	  in	  this	  thesis	  work	  to	  determine	  whether	  a	  loop	  in	  a	  protein	  can	  
move	  in	  a	  certain	  direction	  and	  adopt	  a	  certain	  conformation	  without	  the	  need	  for	  
bond	   rearrangement	  or	   affecting	   the	   structural	   integrity	  of	   the	  protein	   [51].	   I	  will	  
present	  a	  very	  brief	  introduction	  to	  the	  theory	  underlying	  MD	  simulations.	  
	  	   Performing	  an	  MD	  simulation	  involves	  starting	  with	  an	  initial	  atomic	  model	  
(from	   crystallographic	   or	   homology-­‐modeling	   data),	   calculating	   the	   molecular	  
forces	   acting	   upon	   each	   atom,	   moving	   each	   atom	   according	   to	   those	   forces,	   and	  
finally	  advancing	  the	  simulation	  time	  by	  1	  fs.	  This	  process	  is	  repeated	  many	  times,	  
and	  the	  atom	  positions	  and	  velocities	  at	  each	  timestep	  are	  stored	  for	  future	  analysis.	  
To	  simulate	  atomic	  motion,	  the	  equation	  that	  describes	  Newton’s	  second	  law	  
is	  integrated	  for	  each	  atom:	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   (5.6)	  
where	   	   is	   the	   acceleration	  of	   atom	   	   at	   time	   ,	   determined	  by	   the	   force	   	  
acting	  on	  atom	   	  of	  mass	   	  at	  position	   .	  The	  force	   	  acting	  on	  each	  atom	  
can	   be	   estimated,	   in	   the	   simplest	   case,	   by	   taking	   into	   account	   the	   contributions	  




Macromolecules	   are	   modeled	   as	   beads	   connected	   by	   simple	   springs;	   the	   beads	  
represent	   the	   atoms,	   and	   the	   springs	   represent	   the	   covalent	   bonds	   that	   connect	  
them.	   Dihedral	   angles	   are	  modeled	   using	   a	   sinusoidal	   function	   that	   approximates	  
the	   energy	   differences	   between	   eclipsed	   and	   staggered	   conformations.	   Forces	  
arising	   from	   non-­‐bonded	   atoms	   as	   a	   result	   of	   Van	   der	   Waals	   interactions	   are	  
modeled	   using	   the	   Lenard-­‐Jones	   potential,	   and	   forces	   arising	   as	   a	   result	   of	  
electrostatic	  interactions	  are	  modeled	  using	  Coulomb’s	  law.	  To	  make	  the	  simulation	  
a	  more	  accurate	   representation	  of	   the	  actual	  motion	  of	   real	  molecules,	   the	  energy	  
terms	   above	   are	   parameterized	   to	   fit	   experimental	   data	   e.g.	   experimentally	  
determined	  bond	   lengths	  and	  angles	   for	   carbon-­‐carbon	  or	   carbon-­‐nitrogen	  atoms.	  
These	   parameters	   are	   what	   define	   the	   ‘force	   field’;	   contributions	   to	   the	   force	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   In	  practice,	  a	   few	  steps	  are	  required	  to	  prepare	  a	  model	   for	  MD	  simulation.	  
First,	  the	  initial	  atomic	  model	  must	  be	  placed	  in	  an	  explicit	  solvent	  environment,	  and	  
following	  addition	  of	  missing	  atoms	  and	  assignment	  of	  charges	  and	  atom	  types,	  the	  
model	   is	   minimized	   in	   order	   to	   optimize	   the	   coordinates	   towards	   a	   local	   energy	  
minimum.	   Second,	   the	   system	   is	   slowly	  heated	   to	   reach	   the	   temperature	   required	  
for	   the	   simulation.	   Third	   and	   finally	   before	   starting	   the	   simulation,	   the	   system	   is	  
equilibrated	   to	   allow	   the	   system	   to	   relax	   from	  any	  high-­‐energy	   conformation	   that	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A.	  Specificity	  of	  CasL	  and	  MICAL	  Interaction	  
	  
MICAL	  was	   initially	   identified	   in	   a	   far-­‐Western	   screening	   for	   proteins	   that	  
interact	  with	   the	  SH3	  domain	  of	  CasL	  (Crk-­‐associated-­‐substrate	  Lymphocyte	   type)	  
[11].	  Since	  then,	  no	  studies	  on	  the	  interaction	  of	  CasL	  and	  MICAL	  and	  its	  importance	  
have	   been	   reported.	   CasL	   is	   a	   large	  multi-­‐domain	   cytosolic	   protein	   that	   acts	   as	   a	  
scaffold	  and	  is	  important	  for	  intracellular	  signaling	  in	  a	  variety	  of	  processes	  such	  as	  
cell	  migration	  and	  cancer	  metastasis.	  In	  this	  thesis,	  the	  specificity	  of	  the	  interaction	  
of	   CasL	   and	  MICAL	  was	   studied	   by	   Isothermal	   Titration	   Calorimetry	   (ITC),	   and	   a	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A.1	   	   Introduction	  
CasL	   is	   a	   cytosolic	   protein	   part	   of	   the	   p130Cas	   protein	   family	   (contains	  
p130Cas,	   CasL,	   and	   EFS/SIN	   proteins),	   and	   acts	   as	   a	   scaffold	   that	   is	   heavily	  
serine/tyrosine	  phosphorylated	  and	  important	  for	  normal	  and	  pathological	  cellular	  
processes.	  CasL	  is	  important	  for	  transducing	  integrin-­‐mediated	  signals,	  and	  has	  also	  
been	   reported	   to	   function	   downstream	   of	   receptor	   tyrosine	   kinases,	   GPCRs,	   and	  
chemokine	   receptors	   in	   T-­‐cells	   and	   B-­‐cells.	   Proper	   function	   of	   CasL	   is	   crucial	   for	  
processes	  such	  as	  cell	  migration,	  cell	  adhesion,	  apoptosis,	  neurological	  development,	  
proliferation	  and	  differentiation	  of	  normal	  and	  various	  types	  of	  cancer	  cells.	  Cas-­‐L	  is	  
highly	   conserved	   in	   all	   vertebrates;	   and	   no	   homologue	   exists	   in	   other	   lower	  
organisms	  except	  Drosophilla	  (single	  Cas	  protein)	  [54-­‐57].	  
	  CasL	   is	   834	   amino	   acids	   long,	   and	   contains	   multiple	   protein-­‐protein	  
interaction	   sites	   (Figure	   27).	   It	   has	   an	   SH3	   (Src-­‐homology-­‐3)	   domain	   at	   its	   N-­‐
terminus	   (aa	   10-­‐65),	   which	   can	   interact	   with	   other	   proteins	   that	   contain	   a	   poly-­‐
proline	   motif.	   The	   next	   domain	   downstream	   (aa	   ~90-­‐350)	   is	   known	   as	   the	  
“substrate	   domain”	   and	   contains	   repeats	   of	   tyrosine	   motifs	   that	   once	  
phosphorylated	   act	   as	   binding	   sites	   for	   SH2	   domain-­‐containing	   proteins.	   Some	  
studies	   have	   shown	   that	   p130Cas	   (CasL	   homologue	   with	   similar	   domain	  
architecture	  and	  high	  sequence	  similarity)	  can	  act	  as	  a	  mechanosensor;	  extension	  of	  
the	  substrate	  domain	  by	  an	  external	  force	  is	  sufficient	  to	  open	  up	  the	  tyrosine	  motifs	  
and	   allow	   their	   phosphorylation,	   and	   thus	   the	   substrate	   domain	   itself	   is	  
unstructured	   [58,	   59].	   The	   following	   region	   between	   amino	   acids	   350-­‐650	   is	   a	  
	  
	   88	  
serine-­‐rich	  region	  that	  has	  a	   four-­‐helix	  bundle	  structure,	  and	  is	  also	  an	  interaction	  
site	   for	   other	   protein	   partners	   [60].	   Finally,	   the	   carboxy-­‐terminal	   domain	   that	   is	  
highly	   conserved	   amongst	   all	   Cas	   family	   proteins	   has	   a	   FAT	   (Focal	   Adhesion	  
Targeting)	   domain	   fold	   that	   also	   gets	   phosphorylated	   and	   forms	   binding	   sites	   for	  
other	  partner	  proteins	  [61].	  
Integrin	   receptors	   are	   transmembrane	   proteins	   that	   mediate	   cell-­‐cell	   and	  
cell-­‐matrix	   contacts	   at	   focal	   adhesions.	   Signalling	   through	   integrin	   receptors	   leads	  
to	  signal	  transduction	  required	  for	  cell	  adhesion,	  migration,	  apoptosis,	  proliferation,	  
and	  differentiation.	  Upon	  stimulation	  of	  integrins,	  CasL	  and/or	  p130Cas	  move	  from	  
the	  cytosol	  to	  the	  focal	  adhesion	  region,	  where	  they	  perform	  a	  scaffolding	  function,	  
physically	   linking	  many	   proteins	   together	   to	   transduce	   the	   required	   downstream	  
signals	  and	  becoming	  hyper-­‐phosphorylated	  in	  the	  process.	  CasL	  phosphorylation	  is	  
in	  part	  influenced	  by	  the	  state	  of	  actin	  filaments,	  as	  disruption	  of	  actin	  filaments	  was	  
shown	  to	  lead	  to	  dephosphorylation	  of	  CasL	  [55].	  
Cell	   migration	   and	   axon	   extension	   share	   parallel	   features	   such	   as	  
coordination	   of	   actin	   dynamics	   in	   response	   to	   external	   signals.	   Studies	   show	   that	  
CasL	  is	  phosphorylated	  in	  cerebral	  cortex	  and	  hippocampus	  neurons.	  Of	  particular	  
relevance	  to	  MICAL	  and	  axon	  guidance,	  Drosophilla	  Cas	  (DCas)	  has	  been	  shown	  to	  be	  
required	   for	   axon	   guidance	   during	   development	   [62].	   Specifically,	   it	   functions	  
downstream	  of	   integrin	  receptors	  and	  regulates	   the	  degree	  of	   fasciculation	  among	  
axons.	   This	   function	   is	   highly	   dependent	   on	   the	   SH3	   domain,	   and	   DCasSH3	   shares	  
62%	   sequence	   identity	   to	   CasLSH3	   domain.	   Interestingly,	   both	  gain-­‐of-­‐function	   and	  
loss-­‐of-­‐function	  mutants	  of	  DCas	  showed	  a	  decrease	  in	  axon	  defasiculation	  compared	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with	  the	  wild	  type,	  indicating	  that	  the	  function	  of	  DCas	  is	  necessary	  but	  not	  sufficient	  
for	  proper	  axon	  guidance.	  This	  leads	  to	  the	  hypothesis	  that	  other	  factors	  or	  signaling	  
cascades	   are	   required	   for	  proper	   axon	  defasiculation	   in	   addition	   to	   Integrin/DCas	  
action.	  The	  authors	  of	   this	   study	  mention	   that	   their	  preliminary	  data	   suggests	   the	  
physical	  interaction	  of	  MICAL	  and	  CasL	  is	  functionally	  important	  for	  axon	  guidance.	  
To	  date,	  no	  studies	  on	  the	  interaction	  between	  MICAL	  and	  CasL	  have	  been	  reported.	  
	  	  	  	  In	  this	  thesis	  work,	  the	  initial	  aim	  was	  to	  characterize	  the	  effect	  of	  CasL	  on	  
MICAL’s	   redox	   activity.	   The	   work	   presented	   here	   addresses	   the	   specificity	   of	   the	  
CasL-­‐MICAL	   interaction.	   To	   our	   knowledge,	   the	   work	   outlined	   in	   this	   chapter	  
represents	  the	  first	  biophysical	  characterization	  of	  this	  interaction.	  The	  interaction	  
was	   studied	   by	   ITC	   and	   thermodynamic	   parameters	   of	   the	   binding	   were	  
determined.	   Furthermore,	   the	   homology	   model	   of	   CasLSH3	   bound	   to	   a	   peptide	   of	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A.2	   	   Methods	  
	  
A.2.1	   Expression	  and	  Purification	  of	  CasLSH3	  
Cloning	  
A	  plasmid	  containing	  DNA	  coding	  for	  CasL	  from	  mouse	  (codon-­‐optimized	  for	  
expression	   in	  Escherichia	   coli	   –	  Genescript	   Inc.)	   residues	   2-­‐74	  was	   cloned	   onto	   a	  
pGEX-­‐6P2	  expression	  vector	  containing	  an	  N-­‐terminal	  GST	  tag	  with	  an	  engineered	  
N-­‐terminal	  TEV	  protease	  site,	  and	  used	  to	  transform	  Escherichia	  coli	  BL21.	  	  
	  
Protein	  expression	  and	  purification	  
Cells	  were	  grown	  for	  4	  hours	  at	  37°C	  in	  LB	  media	  and	  protein	  expression	  was	  
induced	   by	   addition	   of	   0.5	   mM	   IPTG	   after	   3	   hours,	   before	   harvesting	   by	  
centrifugation.	  Cell	  pellets	  were	  lysed	  in	  1X	  PBS	  buffer	  pH	  7.3	  containing	  1mM	  DTT,	  
0.5	  mM	  EDTA,	  and	  2	  complete	  EDTA-­‐free	  protease	   inhibitor	  cocktail	  pills	   (Roche),	  
and	   the	   protein	   was	   purified	   by	   GST-­‐Sepharose	   affinity	   chromatography	   with	   a	  
gradient	   of	   50	  mM	  Tris-­‐HCl	  pH	  8.0,	   0-­‐20	  mM	  glutathione.	  The	   eluted	  protein	  was	  
digested	  overnight	  with	  TEV	  protease	  to	  remove	  the	  GST-­‐tag,	  and	  buffer	  exchanged	  
to	   50	  mM	  Tris-­‐HCl	   pH	  7.0,	   200	  mM	  Glycine	   using	   a	  HiTrap	  Desalting	   column	   (GE	  
Healthcare).	   The	   cleaved	   product	   was	   purified	   by	   using	   a	   Source	   15Q	   anion	  
exchange	   column,	   eluting	   with	   50	  mM	   Tris-­‐HCl	   pH	   7.0,	   and	   0-­‐1	   M	   NaCl	   gradient	  
(Figure	  28).	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Although	   a	   high	   yield	   (e.g.	   ~	   30	  ml	   at	   ~	   3	  mg/ml)	   of	   purified	   GST-­‐tagged	  
CasLSH3	   and/or	   untagged	   CasLSH3	   can	   be	   readily	   obtained,	   it	   was	   not	   possible	   to	  
concentrate	   a	   sample	   of	   CasLSH3	   beyond	   5	   mg/ml,	   perhaps	   as	   a	   result	   of	  
precipitation	  of	  the	  protein	  at	  the	  membrane	  of	  the	  typically	  used	  centrifugal	  filters.	  
Attempts	   to	   concentrate	   the	  protein	   in	   a	  dialysis	  bag	  over	  PEG	   flakes	   also	  proved	  
unfruitful.	  Lyophillization	  of	   the	   sample	  was	  also	  attempted,	  but	   the	   reconstituted	  
protein	   solution	  was	  only	   as	  high	   as	  ~	  8	  mg/ml.	  This	   could	  be	   further	  optimized,	  
testing	  with	  an	  appropriate	  volatile	  buffer	  prior	  to	  lyophilizing.	  	  
	  
A.2.2	   Expression	  and	  Purification	  of	  CasL	  
Cloning	  
A	  plasmid	  containing	  DNA	  coding	  for	  CasL	  from	  mouse	  (codon-­‐optimized	  for	  
expression	   in	   Escherichia	   coli	   –	   Genescript	   Inc.)	   was	   cloned	   onto	   a	   pGEX-­‐6P2	  
expression	  vector	  containing	  an	  N-­‐terminal	  GST	  tag	  with	  an	  engineered	  N-­‐terminal	  
TEV	  protease	  site,	  and	  used	  to	  transform	  Escherichia	  coli	  BL21.	  	  
	  
Protein	  expression	  and	  purification	  
Cells	  were	  grown	  for	  4	  hours	  at	  37°C	  in	  LB	  media	  and	  protein	  expression	  was	  
induced	   by	   addition	   of	   0.5	   mM	   IPTG	   after	   3	   hours,	   before	   harvesting	   by	  
centrifugation.	   Cell	   pellets	   were	   lysed	   in	   1X	   PBS	   buffer	   pH	   7.3	   containing	   0.1	   %	  
Tween-­‐20,	  2	  mM	  DTT,	  5	  mM	  MgCl2,	  10	  %	  v/v	  glycerol,	  and	  2	  complete	  EDTA-­‐free	  
protease	   inhibitor	   cocktail	   pills	   (Roche),	   and	   the	   protein	   was	   purified	   by	   GST-­‐
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Sepharose	  affinity	  chromatography	  with	  a	  gradient	  of	  50	  mM	  Tris-­‐HCl	  pH	  8.0,	  0-­‐20	  
mM	  glutathione.	  This	  step	  usually	  yields	  ~	  45	  ml	  of	  ~	  0.6	  mg/ml	  of	  GST-­‐tagged	  CasL.	  
The	  eluted	  protein	  was	  digested	  overnight	  with	  TEV	  protease	   to	   remove	   the	  GST-­‐
tag,	  and	  buffer	  exchanged	  to	  1X	  PBS	  buffer	  pH	  7.3	  (Figure	  29).	  The	  cleaved	  product	  
was	   purified	   first	   by	   GST-­‐sepharose	   affinity	   chromatography	   to	   remove	   uncut	  
protein	  and	  the	  GST	  tag,	  followed	  by	  buffer	  exchange	  to	  50	  mM	  Tris-­‐HCl	  pH	  7.0,	  200	  
mM	  sucrose,	  10	  %	  v/v	  glycerol	   and	   finally	  by	  using	  a	  Source	  15Q	  anion	  exchange	  
column,	  eluting	  with	  50	  mM	  Tris-­‐HCl	  pH	  7.0,	  and	  0-­‐1	  M	  NaCl	  gradient	  (Figure	  30).	  
This	  step	  usually	  yields	  ~	  30	  ml	  of	  	  ~	  0.5	  mg/ml.	  
	  
A.2.3	   Isothermal	  Titration	  Calorimetry	  
ITC	   is	   a	   method	   where	   both	   a	   sample	   cell	   and	   reference	   cell	   are	   kept	   at	  
constant	  slow	  temperature	  jump,	  and	  upon	  injection	  of	  a	  protein	  or	  small	  molecule	  
(e.g.	  ligand,	  peptide,	  drug,	  etc.)	  that	  binds	  with	  a	  macromolecule	  in	  the	  sample	  cell,	  
the	   heat	   required	   to	   keep	   the	   temperature	   of	   the	   sample	   and	   reference	   cells	   the	  
same	   is	   recorded.	   A	   number	   of	   successive	   injections	   of	   injectant	   are	   performed.	  
From	   this	   experiment,	   thermodynamic	   parameters	   such	   as	   equilibrium	   binding	  
constant,	  free	  energy,	  enthalpy,	  and	  entropy	  of	  binding	  can	  be	  determined.	  
	  ITC	  experiments	  were	   carried	  out	  using	  120	  µM	  GST-­‐tagged	  CasLSH3	   and	  a	  
peptide	   containing	   either	   wild	   type	   MICAL’s	   poly-­‐proline	   sequence	  
(SGAEPPPKPPRS)	   or	   peptides	   containing	  mutated	   sequence	  where	   an	   Ala,	   Glu,	   or	  
Trp	  replaces	  the	  Lys.	  A	  VP-­‐ITC	  Microcal	  calorimeter	  was	  used,	  and	  the	  experiment	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was	  carried	  out	  at	  27˚C.	  All	  reagents	  were	   in	  50	  mM	  HEPES	  pH	  7.3,	  200	  mM	  NaCl.	  
The	   sample	   cell	   contained	   2	  ml	   of	   the	   GST-­‐tagged	   CasLSH3,	   and	   1.2	  mM	   of	  MICAL	  
peptide	  (wild-­‐type	  or	  mutant)	  was	  added	  over	  25	  injections	  of	  10	  µl	  each.	  
	  
A.2.4	   Homology	  Modeling	  of	  CasL	  and	  MICAL	  
A	  homology	  model	  of	  CasLSH3	  was	  built	  based	  on	  the	  crystal	  structure	  of	  the	  
SH3	  domain	  of	  c-­‐Crk	  bound	  to	  a	  peptide	  consisting	  of	  a	  poly-­‐proline	  sequence	  from	  
its	   protein	   interactor	   (PDB	   1CKB)	   [63].	   The	   model	   was	   built	   using	   the	   software	  
MOE.	   A	   peptide	   consisting	   of	   the	   poly-­‐proline	   sequence	   of	   MICAL	   PPPKPPR	   was	  
modeled	  and	  minimized	  in	  MOE,	  and	  aligned	  to	  the	  poly-­‐proline	  peptide	  originally	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A.3	   	   Results	  
	  
A.3.1	   Binding	  of	  CasL	  to	  MICAL	  
	   The	  binding	  of	  CasL	  and	  MICAL	  was	  studied	  by	  ITC,	  using	  the	  SH3	  domain	  of	  
CasL	  as	  the	  macromolecule,	  and	  a	  peptide	  containing	  MICAL’s	  poly-­‐proline	  sequence	  
as	   the	   injectant.	   Binding	   occurs	   with	   a	   KD	   of	   ~	   175	   µM,	   a	   favorable	   enthalpy	   of	  
binding	  –	  8	  kcal	  mol-­‐1,	  and	  an	  unfavorable	  entropy	  upon	  binding	  of	  –	  9.5	  cal	  K-­‐1	  mol-­‐
1.	  The	  unfavorable	  entropy	  is	  most	  likely	  due	  to	  the	  sequence	  being	  on	  a	  peptide	  that	  
has	   a	   large	   conformational	   entropy,	   and	  not	   part	   of	   the	   full-­‐length	  MICAL	  protein	  
where	  it	  will	  have	  significantly	  less	  conformational	  entropy	  (Figure	  31).	  
	  	   When	  peptides	  containing	  mutant	  MICAL	  poly-­‐proline	  sequences	  (Lys	  to	  Ala,	  
Glu,	   or	   Trp)	  were	   tested	   for	   binding	   to	   CasLSH3	   by	   ITC,	   all	  mutant	   peptides	   either	  
failed	  to	  bind,	  or	  bound	  with	  very	  low	  affinity	  that	  is	  not	  detectable	  by	  ITC	  (Figure	  
31).	  This	   implicates	  the	  Lysine	  residue	   in	  the	  poly-­‐proline	  sequence	  as	  key	  for	  the	  
specificity	   of	   the	   interaction.	   Binding	   to	   the	   mutant	   peptides	   is	   exothermic	   as	  
opposed	  to	  endothermic	  for	  the	  wild-­‐type	  peptide,	  but	  the	  enthalpy	  is	  on	  the	  order	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A.3.2	   Homology	   Model:	   Residues	   Potentially	  
Important	  for	  Recognition	  
	   A	   homology	   model	   of	   CasLSH3	   bound	   to	   MICAL’s	   poly-­‐proline	   sequence	  
peptide	   was	   constructed	   using	   the	   crystal	   structure	   of	   the	   SH3	   domain	   of	   c-­‐Crk	  
bound	   to	   its	   poly-­‐proline	   peptide	   as	   a	   template	   (PDB	   1CKB).	   The	   model	   shows	  
structural	   features	   of	   the	   binding	   site	   that	   could	   explain	   the	   specificity	   of	   the	  
interaction	  and	  the	  importance	  of	  the	  Lys	  in	  MICAL’s	  poly-­‐proline	  sequence	  in	  this	  
interaction.	  	  
	   Structural	   analysis	   of	   c-­‐CrkSH3	   bound	   to	   its	   PPVPP	   peptide	   shows	   the	  
hydrophobic	  nature	  of	   the	   interaction	   (Figure	  32).	  The	  Pro,	  Tyr,	   and	  Phe	   residues	  
along	   with	   the	   6-­‐membered-­‐ring	   of	   the	   Trp	   side	   chain	   provide	   a	   hydrophobic	  
environment	   to	   accommodate	   the	   Val	   from	   the	   poly-­‐proline	   peptide.	   This	   SH3	  
domain	  would	  not	  be	  able	  to	  accommodate	  a	  Lys	  in	  the	  position	  of	  the	  Val	  because	  
of	  the	  hydrophobic	  environment	  and	  steric	  clashes	  as	  the	  Lys	  has	  a	  larger	  side	  chain.	  	  
Analysis	   of	   the	  model	   of	   CasLSH3	   shows	   that	   there	   is	   a	   deeper	   binding	   site	  
ideal	  for	  a	  Lys	  side	  chain,	  and	  a	  less	  hydrophobic/more	  polar	  environment,	  evident	  
upon	  alignment	  with	   c-­‐CrkSH3.	   Specifically,	   the	  Tyr	  of	   c-­‐CrkSH3	   is	   an	  Arg	   instead	   in	  
CasLSH3;	  the	  bulky	  Phe	  side	  chain	  of	  c-­‐CrkSH3	  is	  an	  Asn	  instead	  in	  CasLSH3,	  and	  the	  Trp	  
side	  chain	   is	  shifted	  outwards	  making	   the	  binding	  pocket	   larger.	  Furthermore,	   the	  
side	   chain	   of	   an	   Asp	   residue	   inside	   the	   binding	   pocket	   of	   CasLSH3	   can	   adopt	   a	  
conformation	   pointing	   towards	   the	   Lys	   of	   the	   poly-­‐proline	   peptide,	   forming	   a	  
potential	  salt	  bridge.	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A.4	   	   Conclusions	  and	  Discussion	  
	   Both	  an	  experimental	  and	  a	  computational	  approach	  were	  used	   in	  order	   to	  
gain	   insight	   into	   the	   thermodynamics	   and	   specificity	   of	   the	   interaction	   between	  
MICAL	  and	  CasL.	  
	   Experimentally,	  the	  binding	  of	  a	  peptide	  of	  MICAL’s	  poly-­‐proline	  sequence	  to	  
CasLSH3	  was	  monitored	  by	  ITC.	  Mutational	  analysis	  implicates	  the	  Lys	  in	  the	  PPKPP	  
sequence	  of	  MICAL	  as	  critical	  for	  the	  interaction,	  since	  the	  single	  substitution	  of	  the	  
Lys	  for	  Ala	  (smaller	  side	  chain),	  Glu	  (opposite	  charge	  of	  Lys),	  or	  Trp	  (larger,	  bulkier	  
side	  chain)	  was	  enough	  to	  abolish	  binding.	  This	  suggests	  that	  the	  binding	  pocket	  of	  
CasL’s	   SH3	   domain	   is	   less	   hydrophobic	   and	   larger	   than	   that	   of	   c-­‐Crk.	   The	   poly-­‐
proline	   motifs	   that	   typically	   bind	   SH3	   domains	   are	   hydrophobic,	   with	   a	   general	  
consensus	   sequence	   PXXP,	   and	   hence	   hydrophobic	   forces	   drive	   the	   interaction	   of	  
SH3	  domains	  with	   their	   respective	  poly-­‐proline	   sequence	   in	   the	   target	   interacting	  
protein.	   For	   example,	   c-­‐CrkSH3	   domain	   binds	   to	   poly-­‐proline	   sequence	   (PPVPP)	  
whereas	  CasLSH3	  binds	  to	  MICAL’s	  poly-­‐proline	  sequence	  (PPKPP)	  containing	  a	  Lys	  
instead	  of	  the	  Val.	  
To	   gain	   further	   support	   for	   the	   SH3	   domain	   of	   CasL	   having	   a	   different	  
binding	   pocket	   than	   other	   hydrophobic	   SH3	   domains,	   a	   computational	   approach	  
was	  used	  to	  build	  a	  homology	  model	  of	  CasLSH3	  and	  bound	  to	  a	  peptide	  of	  MICAL’s	  
poly-­‐proline	   sequence.	   The	   model	   reveals	   that	   the	   binding	   pocket	   of	   CasLSH3	   is	  
indeed	   larger	   and	  more	   polar	   than	   that	   of	   c-­‐CrkSH3,	   and	   this	   could	   be	   the	   reason	  
behind	  the	  specificity	  of	  the	  interaction	  between	  CasL	  and	  MICAL.	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Figure	  28.	  Purification	  of	  CasLSH3.	  
(A)	  Purification	  of	  CasLSH3	  with	  glutathione	  sepharose	  affinity	  chromatography.	  Left:	  
chromatogram	  from	  a	  GSTPrepTM	  FF	  16/10	  column	  (GE).	  Middle:	  SDS-­‐PAGE	  analysis	  
of	  the	  purification	  from	  this	  step.	  MW:	  Molecular	  weight	  marker	  in	  kDa.	  GST-­‐CasLSH3	  
represents	  a	  mixture	  of	  all	  the	  fractions	  corresponding	  to	  the	  peak.	  Right:	  SDS-­‐PAGE	  
analysis	  of	  the	  GST	  tag	  removal	  using	  TEV	  protease.	  (B)	  Left:	  chromatogram	  from	  a	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Figure	  29.	  Purification	  of	  CasL:	  Affinity	  chromatography	  and	  tag	  cleavage.	  	  
(A)	   Purification	   of	   CasL	  with	   glutathione	   sepharose	   affinity	   chromatography.	   Left:	  
chromatogram	  from	  a	  GSTPrepTM	  FF	  16/10	  column	  (GE).	  right:	  SDS-­‐PAGE	  analysis	  
of	   the	   purification	   from	   this	   step.	  MW:	  Molecular	  weight	  marker	   in	   kDa.	   (B)	   SDS-­‐
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Figure	  30.	  Purification	  of	  CasL:	  Ion	  exchange	  after	  tag	  removal.	  
(A)	   Purification	   of	   cleaved	   CasL,	   TEV,	   GST	   tag,	   and	   GST-­‐CasL	   with	   glutathione	  
sepharose	   affinity	   chromatography.	   Left:	   chromatogram	   from	   a	   GSTPrepTM	   FF	  
16/10	  column	  (GE).	  right:	  SDS-­‐PAGE	  analysis	  of	  the	  purification	  from	  this	  step.	  (B)	  
Left:	   chromatogram	   from	   a	   SOURCE15Q	   purification.	   Right:	   SDS-­‐PAGE	   analysis	   of	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Figure	  32.	  Homology	  model	  of	  CasLSH3.	  
The	  right	  panel	  is	  a	  close-­‐up	  of	  the	  left	  panel.	  The	  SH3	  domain	  of	  c-­‐Crk	  is	  shown	  in	  
brown	   (PDB	   1CKB),	   while	   CasLSH3	   model	   is	   shown	   in	   green.	   The	   PPKPP	   peptide	  
(MICAL’s	   poly-­‐proline	   sequence)	   is	   shown	   in	   cyan.	   The	   sticks	   shown	   in	   the	   SH3	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  Arab	  Emirates	  
(UAE),	  Abu	  Dhabi,	  UAE	   February	  2014	  
Travel	  award	  
	  
Scholarship	  Coordination	  Office,	  Office	  of	  the	  President	  of	  the	  United	  Arab	  Emirates	  
(UAE),	  Abu	  Dhabi,	  UAE	   August	  2008	  –	  May	  2014	  
Full	  graduate	  scholarship	  including	  tuition	  and	  stipend	  
Johns	  Hopkins	  School	  of	  Medicine	  
	  
Scholarship	  Coordination	  Office,	  Office	  of	  the	  President	  of	  the	  United	  Arab	  Emirates	  
(UAE),	  Abu	  Dhabi,	  UAE	   August	  2004	  –	  May	  2008	  
Full	  undergraduate	  scholarship	  including	  tuition	  and	  stipend	  
University	  of	  Michigan,	  Ann	  Arbor	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Awards	  and	  Honors	  
Poster	   prize,	   BCMB	   Annual	   Retreat,	   BCMB	   program,	   Johns	   Hopkins	   School	   of	  
Medicine,	  Baltimore,	  MD,	  October	  2012.	  
	  
Publications,	  peer	  reviewed	  
Alqassim	   S.	   S.,	   Amzel	   L.	   M.,	   Bianchet	   M.	   A.	   Modulation	   of	   MICAL	   Activity	   by	   the	  
Calponin	  Homology	  Domain:	  Structural	  Insights.	  Manuscript	  in	  preparation.	  
	  
Alqassim	  S.	   S.,	   Urquiza	  M.,	   Bianchet	  V.	  A.,	   Borgnia	  E.,	   Amzel	   L.	  M.,	   Bianchet	  M.	  A.	  
How	   Non-­‐redox	   Domains	   of	   MICAL-­‐1	   Modulate	   its	   Enzymatic	   and	   Actin-­‐binding	  
Activities.	  Manuscript	  in	  preparation.	  
	  
Simon	   O.,	   Alqassim	   S.	   S.,	   Urquiza	   M.,	   Bianchet	   M.	   A.,	   Amzel	   L.	   M.The	   Plexin-­‐A1	  
Intracellular	  Domain	  and	  Rnd1	  Together	  Suffice	  to	  Lift	  Autoinhibition	  of	  MICAL-­‐1's	  
Monooxygenase,	   but	   not	   its	   Actin-­‐Disassembling	   Activities.	   Manuscript	   in	  
preparation.	  
	  
Posters	  and	  Abstracts	  
Alqassim	  S.	   S.,	   Bianchet	  M.	   A.,	   Amzel	   L.	  M.	   Structural	   Insights	   into	  Modulation	   of	  
MICAL	  Activities	   by	   its	   Calponin	  Homology	   (CH)	  Domain.	   Biophysical	   Society	   58th	  
Annual	  Meeting.	  San	  Francisco,	  CA,	  February	  16,	  2014.	  
	  
Alqassim	   S.	   S.,	   Bianchet	   M.	   A.,	   Amzel	   L.	   M.	   Modulation	   of	   MICAL	   Activity	   by	   the	  
Calponin	  Homology	  (CH)	  Domain.	  Institute	  for	  Biophysical	  Research,	  Baltimore,	  MD,	  
September,	  2013.	  
	  
Alqassim	  S.	  S.,	  Simon	  O.,	  Urquiza	  M.,	  Bianchet	  M.	  A.,	  Amzel	  L.	  M.	  Regulation	  of	  the	  
Redox	  Activity	  of	  MICAL.	  BCMB	  Annual	  Retreat,	  Baltimore,	  MD,	  October,	  2012.	  
	  
Alqassim	  S.	  S.,	  Simon	  O.,	  Urquiza	  M.,	  Bianchet	  M.	  A.,	  Amzel	  L.	  M.	  MICAL	  Acting	  on	  
Actin:	  Kinetic	  Studies.	  Institute	  for	  Biophysical	  Research,	  Baltimore,	  MD,	  September,	  
2012.	  
	  
Alqassim	   S.	   S.,	   Bianchet	   M.	   A.,	   Amzel	   L.	   M.	   MICAL	   Acting	   on	   Actin.	   Institute	   for	  
Biophysical	  Research,	  Baltimore,	  MD,	  September,	  2011.	  
	  
Oral	  presentations	  
“An	   Introduction	   to	   the	   Theory	   of	   Protein	   Crystal	   Nucleation.”	   Department	   of	  
Biophysics	  &	  Biophysical	  Chemistry,	   Johns	  Hopkins	  School	  of	  Medicine,	  Baltimore,	  
MD,	  November	  2012.	  
	  
“Role	  of	  Calponin	  Homology	  (CH)	  Domain	  in	  Regulation	  of	  MICAL	  Activities.”	  BCMB	  
Annual	  Retreat,	  Johns	  Hopkins	  School	  of	  Medicine,	  Baltimore,	  MD,	  October	  2011.	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“Role	  of	  Calponin	  Homology	  (CH)	  Domain	  in	  Regulation	  of	  MICAL	  Activitiy	  in	  Axon	  
Guidance.”	   BCMB	   Colloquium,	   Johns	   Hopkins	   School	   of	   Medicine,	   Baltimore,	   MD,	  
October	  2011.	  
	  
Service	  and	  Leadership	  
Laboratory	   Research	  Mentor,	   Eitan	   Borgnia,	   high	   school	   student.	   Laboratory	   of	  
Dr.	   Mario	   Amzel,	   Johns	   Hopkins	   School	   of	   Medicine.	   September	   2013	   –	   January	  
2014.	  
	  
Tutor,	   Biophysics	   and	   Biophysical	   Chemistry,	   Johns	   Hopkins	   School	   of	   Medicine.	  
September	  2013	  –	  January	  14.	  
	  
Writer,	   BCMB	   Community	   Newsletter,	   BCMB	   program,	   Johns	   Hopkins	   School	   of	  
Medicine,	  Baltimore,	  MD.	  http://bcmbnews.com/author/saifaq/.	  September	  2012	  –	  
February	  2013.	  	  
	  
Tutor,	   Biophysics	   and	   Biophysical	   Chemistry,	   Johns	   Hopkins	   School	   of	   Medicine.	  
October	  2012.	  
	  
Committee	   head,	   for	   selection	   and	   invitation	   of	   BCMB	   Annual	   Retreat	   keynote	  
speaker,	  Johns	  Hopkins	  School	  of	  Medicine,	  Baltimore,	  MD.	  October	  2012.	  
	  
Student	   emcee,	   BCMB	   Annual	   Retreat,	   Johns	   Hopkins	   School	   of	   Medicine,	  
Baltimore,	  MD.	  October	  2012.	  
	  
Committee	  member,	  for	  selection	  and	  invitation	  of	  BCMB	  Annual	  Retreat	  keynote	  
speaker,	  Johns	  Hopkins	  School	  of	  Medicine,	  Baltimore,	  MD.	  October	  2011.	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